

CURRICULUM VITAE

INFORMAZIONI PERSONALI

Nome	FEDERICO CAPPUZZO
Indirizzo	
Telefono	
E-mail	federico.cappuzzo@ifo.it
Nazionalità	
Data di nascita	

ESPERIENZA LAVORATIVA

<i>Dal 07 sett. 2020 ad oggi</i>	Direttore di Oncologia Medica 2, IRCCS Istituto Nazionale Tumori Regina Elena, Roma
<i>Da apr. 2017</i>	Abilitazione Scientifica Nazionale a Professore Ordinario in Oncologia
<i>Dal 17 apr. 2016 al 06 sett. 2020</i>	Direttore Unità Operativa Complessa di Oncologia presso la AUSL della Romagna
<i>Da dic. 2016 al 06 sett. 2020</i>	Direttore del Dipartimento di Oncologia e Ematologia presso la AUSL della Romagna
<i>Da dic. 2010 al 17 apr. 2016</i>	Direttore del Dipartimento di Oncologia Medica dell'USL6 di Livorno
<i>Da genn. 2010 al 17 apr. 2016</i>	Direttore Unità Operativa Complessa di Oncologia Medica presso L'Ospedale Civile di Livorno
<i>Da nov. 2006 a genn. 2010</i>	Aiuto presso la Divisione di Oncologia ed Ematologia dell'Istituto Clinico Humanitas IRCCS di Rozzano (Milano).
<i>Da dic. 2004 a nov. 2006</i>	Dirigente medico di I livello presso la Divisione di Oncologia Medica dell'Ospedale Bellaria di Bologna.
<i>Da genn. 2004 a nov. 2004</i>	Comando finalizzato alla ricerca sui tumori polmonari presso l'University of Colorado Cancer Center di Denver (Colorado-USA).
<i>Da nov. 2000 a genn. 2004</i>	Dirigente medico di I livello presso la Divisione di Oncologia Medica dell'Ospedale Bellaria di Bologna.

ISTRUZIONE E FORMAZIONE

<i>05 nov. 1992</i>	Laurea in Medicina e Chirurgia presso l'Università degli Studi di Palermo, con 110/110 lode e menzione di merito.
<i>12 nov. 1996</i>	Diploma di Specializzazione in Oncologia Medica presso l'Università degli Studi di Milano con 70/70 e lode.
<i>Sett. 1997</i>	Certificazione Europea in Oncologia Medica (European Society for Clinical Oncology Certification in Medical Oncology).
<i>Dal 01 ott. 1993 al 05 nov. 1996</i>	Specializzando in Oncologia presso la Divisione di Oncologia Medica B dell'Istituto Nazionale per lo studio e la cura dei Tumori di Milano.
<i>Dal 05 nov. 1996 al 30 giu. 1997</i>	Fellowship in oncologia medica presso la Divisione di Oncologia Medica B dell'Istituto Nazionale per lo studio e la cura dei Tumori di Milano per la conduzione di studi clinici sul tumore della mammella e tumori gastroenterici.

- Da ago. 1997 a sett. 1999* Fellowship in oncologia toracica presso la Divisione di Oncologia Toracica dell'Institut Gustave Roussy in Villejuif (Parigi), per la conduzione di studi sulla terapia genica dei tumori polmonari e il trattamento ad alte dosi dei microcitomi.
- Da ott. 1999 a febr. 2000* Fellowship in oncologia toracica presso la Divisione di Oncologia Medica dell'Ospedale Bellaria di Bologna.
- Da mar. 2000 a sett. 2000* Fellowship in oncologia toracica presso la Medical University of South Carolina in Charleston (USA) per la conduzione di studi di ricerca traslazionale.

MADRELINGUA

ITALIANO

ALTRE LINGUE

INGLESE

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

Eccellente
Eccellente
Eccellente

FRANCESE

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

Eccellente
Eccellente
Eccellente

AFFILIAZIONE A SOCIETÀ SCIENTIFICHE ED EDITORIAL BOARDS

- Da genn. 1994* Membro della Società Italiana di Oncologia Medica (AIOM)
- Da mar. 1996* Membro della Società Europea di Oncologia Medica (ESMO)
- Da aprile 2001* Membro della Società Americana di Oncologia Clinica (ASCO)
- Da giu. 2004* Membro della International Association for the Study of Lung Cancer (IASCL)
- Da mag. 2006* Membro dell'editorial board della rivista Lung Cancer
- Dal 2013 al 2017* Chairman dell'Educational Committee dell'Associazione Internazionale per lo Studio dei Tumori Polmonari (IASLC)

GRANTS

- 1996* Grant annuale dell'Istituto Nazionale per lo studio e la cura dei Tumori di Milano
- 1997-1999* Grant biennale della Società Europea di Oncologia Medica (ESMO) per la conduzione di studi sulla terapia genica nei tumori polmonari
- 2000* Grant annuale della Eli-Lilly per lo studio delle neoplasie polmonari.
- 2006-2008* Finanziamento triennale da parte dell'associazione Italiana per la Ricerca sul Cancro (AIRC) per la conduzione di uno studio randomizzato di fase III con inibitori delle tirosino-kinasi in pazienti con carcinoma polmonare non a piccole cellule con amplificazione/polisomia del gene che codifica per EGFR.
- 2009-2011* Finanziamento triennale da parte dell'associazione Italiana per la Ricerca sul Cancro (AIRC) per la conduzione di uno studio di ricerca traslazionale sul ruolo di MET quale fattore predittivo di resistenza ad agenti anti-EGFR nei tumori del polmone e del colon-retto.

- 2012-2014 Finanziamento triennale da parte dell'associazione Italiana per la Ricerca sul Cancro (AIRC) per la conduzione di uno studio di ricerca sulle cellule staminali tumorali nel cancro del polmone (studio LUCAS).
- 2007-2008 Finanziamenti per la conduzione di studi di ricerca traslazionale nell'ambito delle neoplasie polmonari da parte di ROCHE e ASTRAZENECA.
- 2012-2013 Research grant dall' Istituto Toscano Tumori su "MIR128 and LET7 expression and efficacy of anti-EGFR therapies in metastatic NSCLC with EGFR or KRAS mutations".
- 2014 Research grant dalla Fondazione Ricerca Traslazionale (FoRT) per lo studio "Crizotinib in pretreated metastatic non-small-cell lung cancer with MET amplification or ROS1 translocation (METROS)".
- 2016 Research grant dalla Fondazione Ricerca Traslazionale (FoRT) per lo studio "SQUINT (Squamous Immunotherapy Nivolumab Trial): An open-label, randomized, phase II trial of nivolumab-ipilimumab versus platinum-based chemotherapy in chemo-naïve metastatic or recurrent Squamous-Cell Lung Cancer (SqLC)".
- 2016 Research grant dalla Fondazione Ricerca Traslazionale (FoRT) per lo studio "PF-06463922 for crizotinib pretreated ROS1 positive non-small-cell lung cancer: a phase II Trial (PFROST)".
- 2017 Research grant dalla Fondazione Ricerca Traslazionale (FoRT) per lo studio "Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation (CABinMET)
- 2017 Research grant dalla Fondazione Ricerca Traslazionale (FoRT) per lo studio "SpeciALK: Crizotinib in ALK rearranged non-small-cell lung cancer: a retrospective study in patients treated in the Italian named patient use program"
- 2017 Research grant dalla Fondazione Ricerca Traslazionale (FoRT) per lo studio "FLIBER: Serum cytokine levels as predictors of the efficacy of aflibercept in combination with FOLFIRI in metastatic Colo-Rectal Cancer patients (mCRC)"
- 2018 Research grant dalla Fondazione Ricerca Traslazionale (FoRT) per lo studio "Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1+ advanced metastatic non-small-cell lung cancer patients (BEAT trial)"
- 2018 Research grant dalla Fondazione Ricerca Traslazionale (FoRT) per lo studio "STARDUST: Phase II trial evaluating the efficacy of durvalumab as second-line therapy in Non-Small-Cell Lung Cancer patients receiving concomitant steroids"
- 2019 Research grant dalla Fondazione Ricerca Traslazionale (FoRT) per lo studio CAPLAND: "A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR mutations"
- 2019 Research grant dalla Fondazione Ricerca Traslazionale (FoRT) per lo studio NTRK: "NTRK 1,2,3 rearrangements in patients with solid tumors"

- 2019 Research grant dalla Fondazione Ricerca Traslazionale (FoRT) per lo studio BRICE: “A Phase 1/2 Study Exploring Safety, Tolerability and Efficacy of BRIGatinib in Combination With Cetuximab in Subjects With Advanced EGFR mutated or ALK or ROS1 positive Non-Small Cell Lung Cancer and Expansion Phase in Subjects with Advanced EGFR mutated Non-Small Cell Lung Cancer who are resistant to EGFR tyrosine kinase inhibitors”
- 2019 Research grant dalla Fondazione Ricerca Traslazionale (FoRT) per lo studio” A phase II, two cohorts, randomized trial comparing standard of care versus immune-based combination in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiotherapy and durvalumab”.

BREVETTI

- 2008 Brevetto per i metodi di predizione della risposta clinica agli inibitori delle tirosino-kinasi (United States Patent Application Publication US 2008/0090233).
- 2010 Brevetto per la determinazione di MYC e EIF3H quali fattori predittivi della risposta ad inibitori delle tirosino-kinasi nel carcinoma polmonare non a piccole cellule (pending)

ATTIVITÀ DI CONSULENZA E PARTECIPAZIONE AD ADVISORY BOARDS

- Dal 2004 ad oggi* Attività di consulenza, speaker a convegni nazionali ed internazionali e partecipazione ad advisory board per ASTRAZENECA, ROCHE, Eli-Lilly, BMS, Merks, Boehringer Ingelheim, Glaxo, Clovis, Abbott, MSD, Takeda.

ATTIVITA' CONGRESSUALE

- Dal 2000 ad oggi* Oltre 500 presentazioni orali a eventi nazionali e internazionali inclusi
ASCO (2004, 2007, 2009, 2014), **ESMO/ECCO** (2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2019)
World Conference Lung Cancer (WCLC, 2003, 2005, 2007, 2009, 2011, 2013, 2015, 2016, 2017, 2018, 2019)
AIOM (tutti gli anni dal 2004)

GOOGLE SCHOLAR

<https://scholar.google.it/citations?user=BcSTvHYAAAAAJ&hl=it>

Ultimo aggiornamento 25.01.2022

	Tutte	Dal 2017
Citazioni	42061	20194
Indice H	77	54
i10-index	227	162

PUBMED 261

1. Banna GL, Tiseo M, Cortinovis DL, Facchinetti F, Aerts JGJV, Baldessari C, Giusti R, Bria E, Grossi F, Berardi R, Morabito A, Catino A, Genova C, Mazzoni F, Gelibter A, Rastelli F, Macerelli M, Chiari R, Gori S, Mansueto G, Citarella F, Cantini L, Rijavec E, Bertolini F, **Cappuzzo F**, De Toma A, Friedlaender A, Metro G, Pensieri MV, Porzio G, Ficorella C, Pinato DJ, Cortellini A, Addeo A. Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 $\geq 50\%$ metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. *Thorac Cancer*. 2021 Dec 22. doi: 10.1111/1759-7714.14256.
2. Bravaccini S, Bronte G, Petracci E, Puccetti M, D'Arcangelo M, Ravaioli S, Tumedei MM, Maltoni R, Delmonte A, **Cappuzzo F**, Crinò L. The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects. *Front Cell Dev Biol*. 2021 Nov 30; 9:772216. doi: 10.3389/fcell.2021.772216.
3. Melosky B, Kambartel K, Häntschel M, Bennetts M, Nickens DJ, Brinkmann J, Kayser A, Moran M, **Cappuzzo F**. Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis. *Mol Diagn Ther*. 2021 Nov 23. doi: 10.1007/s40291-021-00563-1.
4. Qiu B, Cai K, Chen C, Chen J, Chen KN, Chen QX, Cheng C, Dai TY, Fan J, Fan Z, Hu J, Hu WD, Huang YC, Jiang GN, Jiang J, Jiang T, Jiao WJ, Li HC, Li Q, Liao YD, Liu HX, Liu JF, Liu L, Liu Y, Long H, Luo QQ, Ma HT, Mao NQ, Pan XJ, Tan F, Tan LJ, Tian H, Wang D, Wang WX, Wei L, Wu N, Wu QC, Xiang J, Xu SD, Yang L, Zhang H, Zhang L, Zhang P, Zhang Y, Zhang Z, Zhu K, Zhu Y, Um SW, Oh IJ, Tomita Y, Watanabe S, Nakada T, Seki N, Hida T, Sasada S, Uchino J, Sugimura H, Dermime S, **Cappuzzo F**, Rizzo S, Cho WC, Crucitti P, Longo F, Lee KY, De Ruyscher D, Vanneste BGL, Furqan M, Sieren JC, Yendamuri S, Merrell KW, Molina JR, Metro G, Califano R, Bongiolatti S, Provencio M, Hofman P, Gao S, He J. Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. *Transl Lung Cancer Res*. 2021 Sep;10(9):3713-3736. doi: 10.21037/tlcr-21-634.
5. Minuti G, Stefani A, Carpano S, D'Argento E, Giusti R, Martelli O, Metro G, Gelibter AJ, Antonini Cappellini GC, Carta A, Fadda GM, Nelli F, Ricciardi S, Russano M, Bria E, **Cappuzzo F**. Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia. *Recenti Prog Med*. 2021 Oct;112(10):639-646. doi: 10.1701/3679.36653.
6. Nogami N, Barlesi F, Socinski MA, Reck M, Thomas CA, **Cappuzzo F**, Mok TSK, Finley G, Aerts JG, Orlandi F, Moro-Sibilot D, Jotte RM, Stroyakovskiy D, Villaruz LC, Rodríguez-Abreu D, Lim DW, Merritt D, Coleman S, Lee A, Shankar G, Yu W, Bara I, Nishio M. IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. *J Thorac Oncol*. 2021 Oct 6: S1556-0864(21)03217-2. doi: 10.1016/j.jtho.2021.09.014.
7. Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, Tiseo M, Soto Parra H, Grossi F, **Cappuzzo F**, de Marinis F, Pedrazzoli P, Bonomi M, Gianoncelli L, Perrino M, Santoro A, Zanelli F, Bonelli C, Maconi A, Frega S,

- Gervasi E, Boni L, Ceresoli GL. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol.* 2021 Oct;22(10):1438-1447. doi: 10.1016/S1470-2045(21)00404-6.
8. Scalera S, Mazzotta M, Corleone G, Sperati F, Terrenato I, Krasniqi E, Pizzuti L, Barba M, Vici P, Gallo E, Buglioni S, Visca P, Pescarmona E, Marinelli D, De Nicola F, Ciuffreda L, Goeman F, Fanciulli M, Giusti R, Vecchione A, De Maria R, **Cappuzzo F**, Marchetti P, Ciliberto G, Maugeri-Saccà M. KEAP1 and TP53 frame genomic, evolutionary and immunological subtypes of lung adenocarcinoma with different sensitivity to immunotherapy. *J Thorac Oncol.* 2021 Aug 24;S1556-0864(21)02402-3. doi: 10.1016/j.jtho.2021.08.010.
 9. Mazzotta M, Pizzuti L, Krasniqi E, Di Lisa FS, **Cappuzzo F**, Landi L, Sergi D, Pelle F, Cappelli S, Botti C, Vizza E, Tomao S, Marchetti L, Sanguineti G, Botticelli A, Marchetti P, Magri V, Pisegna S, Venuti A, Tomao F, Buzzacchino F, Ciliberto G, Barba M, Vici P. Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care? *Cancers (Basel).* 2021 Aug 12;13(16):4061. doi: 10.3390/cancers13164061.
 10. Ercolani C, Di Benedetto A, Bonomo C, Visca P, Palange A, Assisi D, Forcella D, Terrenato I, Pescarmona E, Ciliberto G, Cecere FL, **Cappuzzo F**, Buglioni S. Not enough can be enough: feasibility of the Idylla EGFR mutation test when reuse of stained tissue slides is the only option available. *J Clin Pathol.* 2021 Aug 16;jclinpath-2021-207726. doi: 10.1136/jclinpath-2021-207726.
 11. Bronte G, Puccetti M, Petracci E, Landi L, Cravero P, Scodes S, Ulivi P, Ravaioli S, Tumedei MM, Burgio MA, **Cappuzzo F**, Delmonte A, Crinò L, Bravaccini S. The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer. *Front Oncol.* 2021 May 4;11:669839. doi: 10.3389/fonc.2021.669839
 12. Socinski MA, Nishio M, Jotte RM, **Cappuzzo F**, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kong S, Lee A, Coleman S, Zou W, McClelland M, Shankar G, Reck M. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer. *J Thorac Oncol.* 2021 Jul 23;S1556-0864(21)02322-4. doi: 10.1016/j.jtho.2021.07.009.
 13. Gallina FT, Melis E, Forcella D, Mercadante E, Marinelli D, Ceddia S, **Cappuzzo F**, Vari S, Cecere FL, Caterino M, Vidiri A, Visca P, Buglioni S, Sperduti I, Marino M, Facciolo F. Nodal Upstaging Evaluation After Robotic-Assisted Lobectomy for Early-Stage Non-small Cell Lung Cancer Compared to Video-Assisted Thoracic Surgery and Thoracotomy: A Retrospective Single Center Analysis. *Front Surg.* 2021 Jul 1;8:666158. doi: 10.3389/fsurg.2021.666158.
 14. Krasniqi E, Sacconi A, Marinelli D, Pizzuti L, Mazzotta M, Sergi D, Capomolla E, Donzelli S, Carosi M, Bagnato A, Gamucci T, Tomao S, Natoli C, Marchetti P, Grassadonia A, Tinari N, De Tursi M, Vizza E, Ciliberto G, Landi L, **Cappuzzo F**, Barba M, Blandino G, Vici P. MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNomics study. *Biomark Res.* 2021 Jul 13;9(1):57. doi: 10.1186/s40364-021-00289-6.
 15. Krasniqi E, Barba M, Venuti A, Pizzuti L, **Cappuzzo F**, Landi L, Carpano S, Marchetti P, Villa A, Vizza E, Giuliano G, Mazzotta M, Marinelli D, Gnignera S, Vincenzoni C, Stranges V, Sergi D, Giordano A, Tomao F, Maugeri-Saccà M, Sanguineti G, Di Lisa FS, Tomao S, Ciliberto G, Vici P. Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives. *J Clin Med.* 2021 Apr 6;10(7):1525. doi: 10.3390/jcm10071525.
 16. Barba M, Krasniqi E, Pizzuti L, Mazzotta M, Marinelli D, Giuliano G, Di Lisa FS, **Cappuzzo F**, Landi L, Tomao S, Ciliberto G, Vici P. COVID-19 risk in breast

cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience. *Breast J.* 2021 Mar 6. doi: 10.1111/tbj.14204. PMID: 33677841

17. Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, Majem M, Nackaerts K, Syrigos K, Hansen K, Schuette W, Cetnar J, **Cappuzzo F**, Okamoto I, Erman M, Langer SW, Kato T, Groen H, Sun Z, Luo Y, Tanwani P, Caffrey L, Komarnitsky P, Reinmuth N. Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study. *J Thorac Oncol.* 2021 Feb 16:S1556-0864(21)01709-3. doi: 10.1016/j.jtho.2021.02.009. PMID: 33607312
18. Landi L, **Cappuzzo F**. How selecting best upfront therapy for metastatic disease? Focus on ROS1-rearranged disease. *Transl Lung Cancer Res.* 2020 Dec;9(6):2686-2695. doi: 10.21037/tlcr-20-1109. PMID: 33489827
19. Pellini R, Campo F, Sergi D, **Cappuzzo F**. Role of Pembrolizumab in recurrent or metastatic head and neck carcinoma. *Oral Oncol.* 2020 Dec 29:105133. doi: 10.1016/j.oraloncology.2020.105133.
20. Landi L, Ravaglia C, Russo E, Cataleta P, Fusari M, Boschi A, Giannarelli D, Facondini F, Valentini I, Panzini I, Lazzari-Agli L, Bassi P, Marchionni E, Romagnoli R, De Giovanni R, Assirelli M, Baldazzi F, Pieraccini F, Rametta G, Rossi L, Santini L, Valenti I, **Cappuzzo F**. Blockage of interleukin-1 β with canakinumab in patients with Covid-19. *Sci Rep.* 2020 Dec 11;10(1):21775. doi: 10.1038/s41598-020-78492-y. PMID: 33311551
21. Marinelli D, Giusti R, Mazzotta M, Filetti M, Krasniqi E, Pizzuti L, Landi L, Tomao S, **Cappuzzo F**, Ciliberto G, Barba M, Vici P, Marchetti P. Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives. *Crit Rev Oncol Hematol.* 2020 Nov 17;157:103176. doi: 10.1016/j.critrevonc.2020.103176. PMID: 33276183.
22. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. First-Line Lorlatinib or Crizotinib in Advanced *ALK*-Positive Lung Cancer. *N Engl J Med.* 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187.
23. Pagano M, Ceresoli LG, Zucali PA, Pasello G, Garassino M, Grosso F, Tiseo M, Soto Parra H, Zanelli F, **Cappuzzo F**, Grossi F, De Marinis F, Pedrazzoli P, Gnoni R, Bonelli C, Torricelli F, Ciarrocchi A, Normanno N, Pinto C. Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. *Cancers (Basel).* 2020 Oct 13;12(10):E2948. doi: 10.3390/cancers12102948.
24. Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenzov Y, Herbst RS; **ADAURA Investigators**. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. *N Engl J Med.* 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071.
25. Bubendorf L, Conde E, **Cappuzzo F**, Langfort R, Schildhaus HU, Votruba J, Concha-López Á, Esteban-Rodríguez I, Feng J, Devenport J, Boyiddle C, Morris S, Trunzer K, Kerr KM. A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens. *Cancer Cytopathol.* 2020 Jul 28. doi: 10.1002/cncy.22324. Epub ahead of print. PMID: 32721105.
26. Cortellini A, Friedlaender A, Banna GL, Porzio G, Bersanelli M, **Cappuzzo F**, Aerts JGJV, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Berardi R, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Inno A, Di Marino P, Mansueto G, Zoratto F, Santoni M, Tudini M, Ghidini M, Filetti M, Catino A, Pizzutilo P, Sala L, Occhipinti MA, Citarella F, Marco R, Torniai M, Cantini L,

- Follador A, Sforza V, Nigro O, Ferrara MG, D'Argento E, Leonetti A, Pettoruti L, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Bertolini F, Della Gravara L, Dal Bello MG, Belderbos RA, De Filippis M, Cecchi C, Ricciardi S, Donisi C, De Toma A, Proto C, Addeo A, Cantale O, Ricciuti B, Genova C, Morabito A, Santini D, Ficorella C, Cannita K. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression \geq 50% and Their Relationship With Clinical Outcomes. *Clin Lung Cancer*. 2020 Jun 21:S1525-7304(20)30204-7. doi: 10.1016/j.clc.2020.06.010. PMID: 32680806.
27. Früh M, Panje CM, Reck M, Blackhall F, Califano R, **Cappuzzo F**, Besse B, Novello S, Garrido P, Felip E, O'Brien M, Paz Ares L, de Marinis F, Westeel V, De Ruyscher D, Putora PM. Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. *Lung Cancer*. 2020 Aug; 146:6-11. doi:10.1016/j.lungcan.2020.03.024. PMID: 32485661.
 28. Cortellini A, Tiseo M, Banna GL, **Cappuzzo F**, Aerts JGJV, Barbieri F, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Santini D, Berardi R, Morabito A, Genova C, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Santoni M, Tudini M, Rijavec E, Filetti M, Catino A, Pizzutilo P, Sala L, Citarella F, Marco R, Torniai M, Cantini L, Targato G, Sforza V, Nigro O, Ferrara MG, D'Argento E, Buti S, Bordi P, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Della Gravara L, Dal Bello MG, Belderbos RA, Bironzo P, Carnio S, Ricciardi S, Grieco A, De Toma A, Proto C, Friedlaender A, Cantale O, Ricciuti B, Addeo A, Metro G, Ficorella C, Porzio G. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of \geq 50%. *Cancer Immunol Immunother*. 2020 May 30. doi: 10.1007/s00262-020-02613-9. Epub ahead of print. PMID: 32474768.
 29. Cortinovis D, Gemelli M, **Cappuzzo F**. Alectinib Resistance Through Amphiregulin Overexpression: Is Osimertinib the Best Candidate? *J Thorac Oncol*. 2020 Jun;15(6):e92-e93. doi: 10.1016/j.jtho.2020.02.026. PMID: 32471569.
 30. Putora PM, Fischer GF, Früh M, Califano R, Faivre-Finn C, Van Houtte P, McDonald F, Nestle U, Dziadziszko R, Le Pechoux C, Ramella S, Belderbos J, Slotman BJ, Troost EGC, Peeters S, Widder J, Pöttgen C, Reck M, Blackhall F, **Cappuzzo F**, Besse B, Novello S, Garrido P, Felip E, O'Brien M, Paz Ares L, de Marinis F, Westeel V, De Ruyscher D. Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. *Radiother Oncol*. 2020 Aug; 149:84-88. doi: 10.1016/j.radonc.2020.04.015. PMID: 32445987.
 31. Brandes AA, Ardizzoni A, Artioli F, **Cappuzzo F**, Cavanna L, Frassinetti GL, Frassoldati A, Leonardi F, Longo G, Maestri A, Tassinari D, Franceschi E, Nunno VD, Pinto C. Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy. *Future Oncol*. 2020 Jul;16(20):1433-1439. doi: 10.2217/fon-2020-0358. PMID: 32437242.
 32. Jotte R, **Cappuzzo F**, Vynnychenko I, Stroyakovskiy D, Rodríguez-Abreu D, Hussein M, Soo R, Conter HJ, Kozuki T, Huang KC, Graupner V, Sun SW, Hoang T, Jessop H, McClelland M, Ballinger M, Sandler A, Socinski MA. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. *J Thorac Oncol*. 2020 Aug;15(8):1351-1360. doi: 10.1016/j.jtho.2020.03.028. PMID: 32302702.
 33. Landi L, Bruno R, Fontanini G, **Cappuzzo F**. Crizotinib in ROS1 and MET Deregulated NSCLC-Response. *Clin Cancer Res*. 2020 Apr 1;26(7):1775. doi: 10.1158/1078-0432.CCR-20-0026. PMID: 32238412.
 34. Scodes S, **Cappuzzo F**. Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients. *Expert Rev Respir Med*. 2020 Jun;14(6):565-576. doi:10.1080/17476348.2020.1746646. PMID: 32233809.

35. Pezzuto A, **Cappuzzo F**, D'Arcangelo M, Ciccozzi M, Navarini L, Guerrini S, Ricci A, D'Ascanio M, Carico E. Prognostic Value of p16 Protein in Patients With Surgically Treated Non-small Cell Lung Cancer; Relationship With Ki-67 and PD-L1. *Anticancer Res.* 2020 Feb; 40(2):983-990. doi:10.21873/anticancer.14032. PMID: 32014943.
36. Putora PM, Glatzer M, De Ruyscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, **Cappuzzo F**, de Marinis F, Dziaduszek R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O' Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman BJ. Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [*Radiother. Oncol.* 135 (2019) 74-77]. *Radiother Oncol.* 2019 Dec; 141:332. doi: 10.1016/j.radonc.2019.10.006. Erratum for: *Radiother Oncol.* 2019 Jun; 135:74-77. PMID: 31810511.
37. Landi L, D'Inca F, Gelibter A, Chiari R, Grossi F, Delmonte A, Passaro A, Signorelli D, Gelsomino F, Galetta D, Giannarelli D, Soto Parra H, Minuti G, Tiseo M, Migliorino MR, Cognetti F, Toschi L, Bidoli P, Piantadosi F, Calabro' L, **Cappuzzo F**. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. *J Immunother Cancer.* 2019 Nov 21;7(1):316. doi:10.1186/s40425-019-0793-8. PMID: 31752994
38. Gobbini E, Chiari R, Pizzutillo P, Bordi P, Ghilardi L, Pilotto S, Osman G, **Cappuzzo F**, Cecere F, Riccardi F, Scotti V, Martelli O, Borra G, Maiello E, Rossi A, Graziano P, Gregorc V, Casartelli C, Sergi C, Del Conte A, Delmonte A, Bareggi C, Cortinovis D, Rizzo P, Tabbò F, Rossi G, Bria E, Galetta D, Tiseo M, Di Maio M, Novello S. Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study. *Clin Transl Oncol.* 2020 Mar;22(3):294-301. doi:10.1007/s12094-019-02222-8. PMID: 31630357.
39. Chiari R, Ricciuti B, Landi L, Morelli AM, Delmonte A, Spitaleri G, Cortinovis DL, Lamberti G, Facchinetti F, Pilotto S, Verusio C, Chella A, Bonanno L, Galetta D, **Cappuzzo F**. ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). *Clin Lung Cancer.* 2020 Jan;21(1):15-20. doi: 10.1016/j.clcc.2019.06.012. PMID: 31607443.
40. Esposito Abate R, Pasquale R, Sacco A, Piccirillo MC, Morabito A, Bidoli P, Finocchiaro G, Chiari R, Foltran L, Buosi R, Tiseo M, Giannetta L, Battiloro C, Fasola G, Romano G, Ciuffreda L, Frassoldati A, de Marinis F, **Cappuzzo F**, Normanno N. Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib. *Cancers (Basel).* 2019 Sep 25;11(10):1431. doi: 10.3390/cancers11101431. PMID: 31557965
41. Li H, Xu Y, Wan B, Song Y, Zhan P, Hu Y, Zhang Q, Zhang F, Liu H, Li T, Sugimura H, **Cappuzzo F**, Lin D, Lv T; written on behalf of AME Lung Cancer Collaborative Group. The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients. *Transl Lung Cancer Res.* 2019 Aug;8(4):429-449. doi: 10.21037/tlcr.2019.08.04. PMID: 31555517
42. **Cappuzzo F**, West H. Chemoimmunotherapy for stage IV non-small-cell lung cancer - Authors' reply. *Lancet Oncol.* 2019 Sep;20(9):e467. doi:10.1016/S1470-2045(19)30544-3. PMID: 31486366.
43. Landi L, Chiari R, Tiseo M, D'Inca F, Dazzi C, Chella A, Delmonte A, Bonanno L, Giannarelli D, Cortinovis DL, de Marinis F, Borra G, Morabito A, Gridelli C, Galetta D, Barbieri F, Grossi F, Capelletto E, Minuti G, Mazzoni F, Verusio C, Bria E, Ali G, Bruno R, Proietti A, Fontanini G, Crinò L, **Cappuzzo F**. Crizotinib in *<i>MET</i>-Deregulated or *<i>ROS1</i>-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.**

44. Facchinetti F, Pilotto S, Metro G, Baldini E, Bertolaccini L, **Cappuzzo F**, Delmonte A, Gasparini S, Inno A, Marchetti A, Passiglia F, Puma F, Ricardi U, Rossi A, Crinò L, Novello S. Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). *Tumori*. 2019 Jul;105(5_suppl):3-14. doi: 10.1177/0300891619857418. PMID: 31264531.
45. West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, **Cappuzzo F**. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. PMID: 31122901.
46. Putora PM, Glatzer M, De Ruyscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, **Cappuzzo F**, de Marinis F, Dziadziuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, Brien MO, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman BJ. Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. *Radiother Oncol*. 2019 Jun;135:74-77. doi: 10.1016/j.radonc.2019.02.010. Erratum in: *Radiother Oncol*. 2019 Dec; 141:332. PMID: 31015173.
47. Crinò L, Bidoli P, Delmonte A, Grossi F, De Marinis F, Ardizzoni A, Vitiello F, Lo Russo G, Parra HS, Cortesi E, **Cappuzzo F**, Calabrò L, Tiseo M, Turci D, Gamucci T, Antonelli P, Morabito A, Chella A, Giannarelli D, Galetta D. Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. *Oncologist*. 2019 Nov;24(11):e1165-e1171. doi: 10.1634/theoncologist.2018-0737. PMID: 30996007
48. Verzoni E, Carteni G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R, Buti S, Rossetti S, Cognetti F, Rastelli F, Sobrero A, Turci D, Sternberg CN, Porta C, **Cappuzzo F**, Tortora G, Tassinari D, Panni S, Pazzola A, Surico G, Raimondi A, De Giorgi U, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program group. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. *J Immunother Cancer*. 2019 Apr 3;7(1):99. doi: 10.1186/s40425-019-0579-z. PMID: 30944023.
49. Putora PM, Glatzer M, Belderbos J, Besse B, Blackhall F, Califano R, **Cappuzzo F**, de Marinis F, Dziadziuszko R, Felip E, Faivre-Finn C, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O'Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Slotman B, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, De Ruyscher D. Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. *Radiother Oncol*. 2019 Apr; 133:163-166. doi: 10.1016/j.radonc.2018.12.014. PMID: 30935574.
50. Reck M, Mok TSK, Nishio M, Jotte RM, **Cappuzzo F**, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Lee A, Coleman S, Deng Y, Kowanetz M, Shankar G, Lin W, Socinski MA; IMpower150 Study Group. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. *Lancet Respir Med*. 2019 May;7(5):387-401. doi: 10.1016/S2213-2600(19)30084-0. PMID: 30922878.
51. Crinò L, Bronte G, Bidoli P, Cravero P, Minenza E, Cortesi E, Garassino MC,

- Proto C, **Cappuzzo F**, Grossi F, Tonini G, Sarobba MG, Pinotti G, Numico G, Samaritani R, Ciuffreda L, Frassoldati A, Bregni M, Santo A, Piantedosi F, Illiano A, De Marinis F, Tamberi S, Giannarelli D, Delmonte A. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. *Lung Cancer*. 2019 Mar; 129:35-40. doi: 10.1016/j.lungcan.2018.12.025. PMID: 30797489.
52. D'Arcangelo M, D'Incecco A, Ligorio C, Damiani S, Puccetti M, Bravaccini S, Terracciano L, Bennati C, Minuti G, Vecchiarelli S, Landi L, Milesi M, Meroni A, Ravaoli S, Tumedei MM, Incarbone M, **Cappuzzo F**. Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer. *Oncotarget*. 2019 Jan 15;10(5):561-572. doi: 10.18632/oncotarget.26529. PMID: 30728907
53. Passaro A, Prelaj A, Bonanno L, Tiseo M, Tuzi A, Proto C, Chiari R, Rocco D, Genova C, Sini C, Cortinovis D, Pilotto S, Landi L, Bennati C, Camerini A, Toschi L, Putzu C, Cerea G, Spitaleri G, **Cappuzzo F**, de Marinis F. Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. *Clin Lung Cancer*. 2019 Mar;20(2):e186-e194. doi: 10.1016/j.clcc.2018.11.005. PMID: 30563752.
54. Garassino MC, Crinò L, Catino A, Ardizzoni A, Cortesi E, **Cappuzzo F**, Bordi P, Calabrò L, Barbieri F, Santo A, Altavilla G, Ambrosio F, Mini E, Vasile E, Morgillo F, Scoppola A, Bengala C, Follador A, Tedde N, Giannarelli D, Lo Russo G, Vitiello F. Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program. *Tumour Biol*. 2018 Nov;40(11):1010428318815047. doi: 10.1177/1010428318815047. PMID: 30486741.
55. Passiglia F, **Cappuzzo F**, Alabiso O, Bettini AC, Bidoli P, Chiari R, Defferrari C, Delmonte A, Finocchiaro G, Francini G, Gelsomino F, Giannarelli D, Giordano M, Illiano A, Livi L, Martelli O, Natoli C, Puppo G, Ricevuto E, Roca E, Turci D, Galetta D. Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. *Br J Cancer*. 2019 Jan;120(1):57-62. doi: 10.1038/s41416-018-0234-3. PMID: 30377342.
56. Jiang T, Su C, Ren S, **Cappuzzo F**, Rocco G, Palmer JD, van Zandwijk N, Blackhall F, Le X, Pennell NA, Zhou C; written on behalf of the AME Lung Cancer Collaborative Group. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. *J Thorac Dis*. 2018 Jul;10(7):3909-3921. doi: 10.21037/jtd.2018.07.61. PMID: 30174832
57. Zhang Y, Shen J, Simone CB 2nd, **Cappuzzo F**, Fong KM, Rosell R, Chang JY, Ampollini L, Choi JI, He J, Jiang T; Written on behalf of AME Lung Cancer Cooperative Group. How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team. *J Thorac Dis*. 2018 Jun;10(6):3883-3890. doi: 10.21037/jtd.2018.06.101. PMID: 30069390.
58. Grossi F, Crinò L, Logroscino A, Canova S, Delmonte A, Melotti B, Proto C, Gelibter A, **Cappuzzo F**, Turci D, Gamucci T, Antonelli P, Marchetti P, Santoro A, Giusti S, Di Costanzo F, Giustini L, Del Conte A, Livi L, Giannarelli D, de Marinis F. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. *Eur J Cancer*. 2018 Sep; 100:126-134. doi: 10.1016/j.ejca.2018.05.015. PMID: 30014881.
59. De Giorgi U, Cartenì G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, Buti S, Lo Re G, Berruti A, Bracarda S, Cognetti F, Rastelli F, Fornarini G, Porta C, Turci D, Sternberg CN, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program Group. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. *BJU Int*. 2019 Jan;123(1):98-105. doi: 10.1111/bju.14461. PMID: 29956884.

60. Socinski MA, Jotte RM, **Cappuzzo F**, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. *N Engl J Med.* 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. PMID: 29863955.
61. Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, **Cappuzzo F**, Paolini J, Usari T, Tang Y, Wilner KD, Blackhall F, Mok TS. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. *J Clin Oncol.* 2018 Aug 1;36(22):2251-2258. doi: 10.1200/JCO.2017.77.4794. PMID: 29768118.
62. Smit EF, Garon EB, Reck M, **Cappuzzo F**, Bidoli P, Cohen RB, Gao L, O'Brien LM, Lee P, Zimmermann A, Ferry DR, Melemed AS, Pérol M. Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer. *Cancer Chemother Pharmacol.* 2018 Jul;82(1):77-86. doi: 10.1007/s00280-018-3560-5. PMID: 29721850.
63. Vecchiarelli S, Passiglia F, D'Incecco A, Gallo M, De Luca A, Rossi E, D'Incà F, Minuti G, Landi L, Bennati C, Spreafico M, D'Arcangelo M, Mazza V, Normanno N, **Cappuzzo F**. Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC). *Oncotarget.* 2018 Apr 3;9(25):17554-17563. doi: 10.18632/oncotarget.24785. PMID: 29707129.
64. Bertolaccini L, **Cappuzzo F**, Solli P. Lung Cancer Update 2017: from the test tube to the bed. *Ann Transl Med.* 2018 Mar;6(5):86. doi: 10.21037/atm.2018.02.25. PMID: 29666809.
65. **Cappuzzo F**, Landi L. *HER2* Deregulation in Lung Cancer: Right Time to Adopt an Orphan? *Clin Cancer Res.* 2018 Jun 1;24(11):2470-2472. doi:10.1158/1078-0432.CCR-18-0198. PMID: 29496760.
66. Manegold C, Adjei A, Bussolino F, **Cappuzzo F**, Crino L, Dziadziuszko R, Ettinger D, Fennell D, Kerr K, Le Chevalier T, Leigh N, Papotti M, Paz-Ares L, Pérol M, Peters S, Pirker R, Quoix E, Reck M, Smit E, Vokes E, van Zandwijk N, Zhou C. Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. *ESMO Open.* 2017 Jan 13;1(6):e000118. doi: 10.1136/esmoopen-2016-000118. PMID: 29435365.
67. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. *N Engl J Med.* 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. PMID: 29420164.
68. **Cappuzzo F**, Soo R, Hochmair M, Schuler M, Lam KC, Stehle G, Cseh A, Lorence RM, Linden S, Forman ND, Hilbe W, Jazieh AR, Tsai CM. Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies. *Future Oncol.* 2018 Jun;14(15):1477-1486. doi: 10.2217/fon-2017-0666. PMID: 29376400.
69. Reck M, Paz-Ares L, Bidoli P, **Cappuzzo F**, Dakhil S, Moro-Sibilot D, Borghaei H, Johnson M, Jotte R, Pennell NA, Shepherd FA, Tsao A, Thomas M, Carter GC, Chan-Diehl F, Alexandris E, Lee P, Zimmermann A, Sashegyi A, Pérol M. Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. *Lung Cancer.* 2017 Oct; 112:181-187. doi: 10.1016/j.lungcan.2017.07.038. PMID: 29191593.
70. Landi L, **Cappuzzo F**. A few pills twice a day keep ALK-positive non-small-cell

lung cancer at bay. *J Thorac Dis.* 2017 Aug;9(8):2311-2314. doi:10.21037/jtd.2017.07.76. PMID: 28932533.

71. Mazza V, **Cappuzzo F**. Treating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib. *Appl Clin Genet.* 2017 Jul 26;10:49-56. doi: 10.2147/TACG.S103471. PMID: 28794650.
72. Gridelli C, Ardizzoni A, Barberis M, **Cappuzzo F**, Casaluce F, Danesi R, Troncone G, De Marinis F. Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. *Transl Lung Cancer Res.* 2017 Jun;6(3):373-386. doi: 10.21037/tlcr.2017.05.09. PMID: 28713682.
73. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheswaran P, Chen AC, Socinski MA; CheckMate 026 Investigators. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. *N Engl J Med.* 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493. PMID: 28636851.
74. Blackhall F, **Cappuzzo F**. Crizotinib: from discovery to accelerated development to front-line treatment. *Ann Oncol.* 2018 Apr 1;29(4):1073. doi: 10.1093/annonc/mdx121. Erratum for: *Ann Oncol.* 2016 Sep;27 Suppl 3:iii35-iii41. PMID: 28398575.
75. Landi L, **Cappuzzo F**. Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC. *Transl Lung Cancer Res.* 2016 Dec;5(6):579-587. doi: 10.21037/tlcr.2016.12.05. PMID: 28149753.
76. Gemmill RM, Nasarre P, Nair-Menon J, **Cappuzzo F**, Landi L, D'Incecco A, Uramoto H, Yoshida T, Haura EB, Armeson K, Drabkin HA. The neuropilin 2 isoform NRP2b uniquely supports TGF β -mediated progression in lung cancer. *Sci Signal.* 2017 Jan 17;10(462):eaag0528. doi: 10.1126/scisignal.aag0528. PMID: 28096505.
77. Mazza V, **Cappuzzo F**. Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approaches. *J Thorac Dis.* 2016 Oct;8(10):E1348-E1350. doi: 10.21037/jtd.2016.10.99. PMID: 27867624.
78. Drilon A, **Cappuzzo F**, Ou SI, Camidge DR. Targeting MET in Lung Cancer: Will Expectations Finally Be MET? *J Thorac Oncol.* 2017 Jan;12(1):15-26. doi: 10.1016/j.jtho.2016.10.014. PMID: 27794501.
79. Blackhall F, **Cappuzzo F**. Crizotinib: from discovery to accelerated development to front-line treatment. *Ann Oncol.* 2016 Sep;27 Suppl 3: iii35-iii41. doi: 10.1093/annonc/mdw304. Erratum in: *Ann Oncol.* 2018 Apr 1;29(4):1073. PMID: 27573754.
80. **Cappuzzo F**, Morabito A, Normanno N, Bidoli P, Del Conte A, Giannetta L, Montanino A, Mazzoni F, Buosi R, Burgio MA, Cerea G, Chiari R, Cortinovis D, Finocchiaro G, Foltran L, Migliorino MR, Tiseo M, Ferrari S, De Marinis F. Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. *Lung Cancer.* 2016 Sep; 99:31-7. doi: 10.1016/j.lungcan.2016.06.008. PMID: 27565910.
81. Giannini R, Lupi C, Sensi E, Alì G, Proietti A, Boldrini L, Servadio A, Giordano M, Macerola E, Bruno R, Borrelli N, Chella A, Melfi F, Lucchi M, Ribechini A, Vasile E, **Cappuzzo F**, Mussi A, Fontanini G. EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center. *Oncol Rep.* 2016 Aug;36(2):1166-72. doi: 10.3892/or.2016.4874. PMID: 27373829

82. Romanidou O, Landi L, **Cappuzzo F**, Califano R. Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. *Ther Adv Med Oncol*. 2016 May;8(3):176-87. doi: 10.1177/1758834016631531. PMID: 27239236.
83. Van Der Steen N, Giovannetti E, Pauwels P, Peters GJ, Hong DS, **Cappuzzo F**, Hirsch FR, Rolfo C. cMET Exon 14 Skipping: From the Structure to the Clinic. *J Thorac Oncol*. 2016 Sep;11(9):1423-32. doi: 10.1016/j.jtho.2016.05.005. PMID: 27223456.
84. Califano R, Romanidou O, Mountzios G, Landi L, **Cappuzzo F**, Blackhall F. Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies? *Drugs*. 2016 May;76(8):831-40. doi: 10.1007/s40265-016-0578-z. PMID: 27129321.
85. Chatterjee M, Turner DC, Felip E, Lena H, **Cappuzzo F**, Horn L, Garon EB, Hui R, Arkenau HT, Gubens MA, Hellmann MD, Dong D, Li C, Mayawala K, Freshwater T, Ahmadi M, Stone J, Lubiniecki GM, Zhang J, Im E, De Alwis DP, Kondic AG, Fløtten Ø. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. *Ann Oncol*. 2016 Jul;27(7):1291-8. doi: 10.1093/annonc/mdw174. PMID: 27117531.
86. Solomon BJ, **Cappuzzo F**, Felip E, Blackhall FH, Costa DB, Kim DW, Nakagawa K, Wu YL, Mekhail T, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TS. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. *J Clin Oncol*. 2016 Aug 20;34(24):2858-65. doi: 10.1200/JCO.2015.63.5888. PMID: 27022118.
87. Pérol M, Ciuleanu TE, Arrieta O, Prabhaskar K, Syrigos KN, Goksel T, Park K, Kowalyszyn RD, Pikiel J, Lewanski CR, Thomas M, Dakhil S, Kim JH, Karaseva N, Yurasov S, Zimmermann A, Lee P, Carter GC, Reck M, **Cappuzzo F**, Garon EB. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. *Lung Cancer*. 2016 Mar; 93:95-103. doi: 10.1016/j.lungcan.2016.01.007. PMID: 26898621.
88. Del Re M, Tiseo M, Bordi P, D'Incecco A, Camerini A, Petrini I, Lucchesi M, Inno A, Spada D, Vasile E, Citi V, Malpeli G, Testa E, Gori S, Falcone A, Amoroso D, Chella A, **Cappuzzo F**, Ardizzoni A, Scarpa A, Danesi R. Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR- TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. *Oncotarget*. 2017 Feb 21;8(8):13611-13619. doi: 10.18632/oncotarget.6957. PMID: 26799287.
89. Klughammer B, Brugger W, **Cappuzzo F**, Ciuleanu T, Mok T, Reck M, Tan EH, Delmar P, Klingelschmitt G, Yin AY, Spleiss O, Wu L, Shames DS. Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations. *J Thorac Oncol*. 2016 Apr;11(4):545-55. doi: 10.1016/j.jtho.2015.12.107. PMID: 26773740.
90. Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, Giordano M, Garrone O, Levaggi A, Poggio F, Giraudi S, Bighin C, Vecchio C, Sertoli MR, Pronzato P, Del Mastro L; GIM Study Group. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial. *JAMA*. 2015 Dec 22-29;314(24):2632-40. doi: 10.1001/jama.2015.17291. PMID: 26720025.
91. Gasparini P, Cascione L, Landi L, Carasi S, Lovat F, Tibaldi C, Ali G, D'Incecco A, Minuti G, Chella A, Fontanini G, Fassan M, **Cappuzzo F**, Croce CM.

microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers. *Proc Natl Acad Sci U S A*. 2015 Dec 1;112(48):14924-9. doi: 10.1073/pnas.1520329112. PMID: 26627242.

92. Mazières J, Barlesi F, Filleron T, Besse B, Monnet I, Beau-Faller M, Peters S, Dansin E, Früh M, Pless M, Rosell R, Wislez M, Fournel P, Westeel V, **Cappuzzo F**, Cortot A, Moro-Sibilot D, Milia J, Gautschi O. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. *Ann Oncol*. 2016 Feb;27(2):281-6. doi: 10.1093/annonc/mdv573. PMID: 26598547.
93. Landi L, **Cappuzzo F**. Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer. *Expert Rev Clin Pharmacol*. 2016;9(2):203-14. doi: 10.1586/17512433.2016.1122518. PMID: 26582431.
94. Minuti G, D'Incecco A, **Cappuzzo F**. Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly. *Drugs Aging*. 2015 Nov;32(11):907-16. doi: 10.1007/s40266-015-0305-6. PMID: 26446154.
95. Osarogiagbon RU, **Cappuzzo F**, Ciuleanu T, Leon L, Klughammer B. Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials. *Transl Lung Cancer Res*. 2015 Aug;4(4):465-74. doi: 10.3978/j.issn.2218-6751.2015.07.17. PMID: 26380188.
96. Barni S, Maiello E, Di Maio M, Ardizzoni A, **Cappuzzo F**, Maranzano E, Novello S, Bennati C, Ori A, Rizzoli S, Crinò L; RIGHT-3 study group. Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study. *Lung Cancer*. 2015 Nov;90(2):234-42. doi: 10.1016/j.lungcan.2015.08.005. PMID: 26314614.
97. Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulas V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. *Lancet Oncol*. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. PMID: 26156651.
98. Landi L, **Cappuzzo F**. Experience with erlotinib in the treatment of non-small cell lung cancer. *Ther Adv Respir Dis*. 2015 Aug;9(4):146-63. doi: 10.1177/1753465815588053. PMID: 26063687.
99. D'Arcangelo M, Todaro M, Salvini J, Benfante A, Colorito ML, D'Incecco A, Landi L, Apuzzo T, Rossi E, Sani S, Stassi G, **Cappuzzo F**. Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study. *PLoS One*. 2015 May 8;10(5):e0125037. doi: 10.1371/journal.pone.0125037. PMID: 25955492.
100. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Luceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med*. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. PMID: 25891174.
101. Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC,

- Nasroulah F; RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. *Lancet Oncol.* 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Erratum in: *Lancet Oncol.* 2015 Jun;16(6):e262. PMID: 25877855.
102. Rolfo C, Van Der Steen N, Pauwels P, **Cappuzzo F**. Onartuzumab in lung cancer: the fall of Icarus? *Expert Rev Anticancer Ther.* 2015 May;15(5):487-9. doi: 10.1586/14737140.2015.1031219. PMID: 25818471.
 103. Van Der Steen N, Pauwels P, Gil-Bazo I, Castañón E, Raez L, **Cappuzzo F**, Rolfo C. cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance. *Cancers (Basel).* 2015 Mar 25;7(2):556-73. doi: 10.3390/cancers7020556. PMID: 25815459.
 104. Landi L, **Cappuzzo F**. Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer. *Ann Transl Med.* 2015 Mar;3(3):32. doi: 10.3978/j.issn.2305-5839.2015.02.12. PMID: 25815293.
 105. Landi L, **Cappuzzo F**. Targeting MET in NSCLC: looking for a needle in a haystack. *Transl Lung Cancer Res.* 2014 Dec;3(6):389-91. doi: 10.3978/j.issn.2218-6751.2014.11.05. PMID: 25806329.
 106. Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. *Lancet.* 2015 May 9;385(9980):1863-72. doi: 10.1016/S0140-6736(14)62048-1. PMID: 25740286.
 107. Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, **Cappuzzo F**, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. *Lancet Oncol.* 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9. PMID: 25704439.
 108. Mazières J, Zalcman G, Crinò L, Biondani P, Barlesi F, Filleron T, Dingemans AM, Léna H, Monnet I, Rothschild SI, **Cappuzzo F**, Besse B, Thiberville L, Rouvière D, Dziadziuszko R, Smit EF, Wolf J, Spirig C, Pecuchet N, Leenders F, Heuckmann JM, Diebold J, Milia JD, Thomas RK, Gautschi O. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. *J Clin Oncol.* 2015 Mar 20;33(9):992-9. doi: 10.1200/JCO.2014.58.3302. PMID: 25667280.
 109. **Cappuzzo F**, Moro-Sibilot D, Gautschi O, Boleti E, Felip E, Groen HJ, Germonpré P, Meldgaard P, Arriola E, Steele N, Fox J, Schnell P, Engelsberg A, Wolf J. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus. *Lung Cancer.* 2015 Feb;87(2):89-95. doi: 10.1016/j.lungcan.2014.12.010. PMID: 25576294.
 110. Landi L, **Cappuzzo F**. Nit-picking around second line in EGFRwt NSCLC: just an academic effort. *Ann Oncol.* 2015 Mar;26(3):448-50. doi: 10.1093/annonc/mdu575. PMID: 25527415.
 111. **Cappuzzo F**, Finocchiaro G, Grossi F, Bidoli P, Favaretto A, Marchetti A, Valente ML, Cseh A, Clementi L, Massey D, Santoro A. Phase II study of afatinib, an

- irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer. *J Thorac Oncol.* 2015 Apr;10(4):665-72. doi: 10.1097/JTO.0000000000000442. PMID: 25514804.
112. Passiglia F, Van Der Steen N, Raez L, Pauwels P, Gil-Bazo I, Santos E, Santini D, Tesoriere G, Russo A, Bronte G, Zwaenepoel K, **Cappuzzo F**, Rolfo C. The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target? *Curr Drug Targets.* 2014;15(14):1284-92. doi: 10.2174/138945011514141216092739. PMID: 25511614.
 113. Stasi I, **Cappuzzo F**. Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer. *Transl Respir Med.* 2014 Jan 6;2:2. doi: 10.1186/2213-0802-2-2. PMID: 25505694.
 114. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, **Cappuzzo F**, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK- positive lung cancer. *N Engl J Med.* 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440. Erratum in: *N Engl J Med.* 2015 Oct 15;373(16):1582. PMID:25470694.
 115. D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J, Coppi E, Chella A, Fontanini G, Filice ME, Tornillo L, Incensati RM, Sani S, Crinò L, Terracciano L, **Cappuzzo F**. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. *Br J Cancer.* 2015 Jan 6;112(1):95-102. doi: 10.1038/bjc.2014.555. PMID: 25349974.
 116. Landi L, **Cappuzzo F**. Management of NSCLC: focus on crizotinib. *Expert Opin Pharmacother.* 2014 Dec;15(17):2587-97. doi: 10.1517/14656566.2014.970174. PMID: 25301075.
 117. Landi L, Tiseo M, Chiari R, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, Haspinger ER, Cortinovis D, Santo A, Banna G, Catino A, GiajLevra M, Crinò L, de Marinis F, **Cappuzzo F**. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. *Clin Lung Cancer.* 2014 Nov;15(6):411-417.e4. doi: 10.1016/j.clc.2014.07.002. PMID: 25242668.
 118. Landi L, **Cappuzzo F**. Pharmacotherapy targeting the EGFR oncogene in NSCLC. *Expert Opin Pharmacother.* 2014 Nov;15(16):2293-305. doi: 10.1517/14656566.2014.957179. PMID: 25219817.
 119. Stasi I, **Cappuzzo F**. Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer. *Lung Cancer (Auckl).* 2014 Aug 28;5:43-50. doi: 10.2147/LCTT.S37981. PMID: 28210141.
 120. Novello S, Besse B, Felip E, Barlesi F, Mazieres J, Zalzman G, von Pawel J, Reck M, **Cappuzzo F**, Ferry D, Carcereny E, Santoro A, Garcia-Ribas I, Scagliotti G, Soria JC. A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. *Ann Oncol.* 2014 Nov;25(11):2156-2162. doi: 10.1093/annonc/mdu384. PMID: 25139550.
 121. Landi L, **Cappuzzo F**. Ceritinib for the treatment of non-small cell lung cancer. *Drugs Today (Barc).* 2014 Jul;50(7):465-73. doi: 10.1358/dot.2014.50.7.2133568. PMID: 25101329.
 122. Chiari R, Buttitta F, Iacono D, Bennati C, Metro G, Di Lorito A, Iezzi M, Tiseo M, Mazzoni F, **Cappuzzo F**, Marchetti A, Crinò L. Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry- positive lung adenocarcinoma: a case series. *Clin Lung Cancer.* 2014 Nov;15(6):470-4. doi: 10.1016/j.clc.2014.06.004. PMID: 25087901.

123. Martin V, **Cappuzzo F**, Mazzucchelli L, Frattini M. HER2 in solid tumors: more than 10 years under the microscope; where are we now? *Future Oncol.* 2014 Jun;10(8):1469-86. doi: 10.2217/fon.14.19. PMID: 25052756.
124. Geva R, Vecchione L, Kalogeras KT, Jensen BV, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, **Cappuzzo F**, Cervantes A, Frattini M, Fountzilias G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. *Gut.* 2015 Jun;64(6):921-8. doi: 10.1136/gutjnl-2014-307234. PMID: 25011934.
125. Garon EB, Ciuleanu TE, Arrieta O, Prabhaskar K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, **Cappuzzo F**, Alexandris E, Sashegyi A, Yurasov S, Pérol M. Ramucicromab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. *Lancet.* 2014 Aug 23;384(9944):665-73. doi: 10.1016/S0140-6736(14)60845-X. PMID: 24933332.
126. de Marinis F, Ardizzoni A, Fontanini G, Grossi F, **Cappuzzo F**, Novello S, Santo A, Lorusso V, Cortinovis D, Iurlaro M, Galetta D, Gridelli C; LIFE Study Team. Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study. *Clin Lung Cancer.* 2014 Sep;15(5):338-45.e1. doi: 10.1016/j.clcc.2014.04.004. PMID: 24925809.
127. Gridelli C, de Marinis F, Ardizzoni A, Novello S, Fontanini G, **Cappuzzo F**, Grossi F, Santo A, Cortinovis D, Favaretto A, Lorusso V, Galetta D, Siena S, Bettini A, Iurlaro M, Caprioli A; LIFE study team. Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study. *J Cancer Res Clin Oncol.* 2014 Oct;140(10):1783-93. doi: 10.1007/s00432-014-1715-2. PMID: 24903964.
128. Ali G, Proietti A, Pelliccioni S, Niccoli C, Lupi C, Sensi E, Giannini R, Borrelli N, Menghi M, Chella A, Ribechini A, **Cappuzzo F**, Melfi F, Lucchi M, Mussi A, Fontanini G. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. *Arch Pathol Lab Med.* 2014 Nov;138(11):1449-58. doi: 10.5858/arpa.2013-0388-OA. PMID: 24885803.
129. Minuti G, D'Incecco A, Landi L, **Cappuzzo F**. Protein kinase inhibitors to treat non-small-cell lung cancer. *Expert Opin Pharmacother.* 2014 Jun;15(9):1203-13. doi: 10.1517/14656566.2014.909412. PMID: 24745764.
130. Natoli C, Brocco D, Sperduti I, Nuzzo A, Tinari N, De Tursi M, Grassadonia A, Mazzilli L, Iacobelli S, Gamucci T, Vici P; "FOLLOW-UP" Study Group. Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey. *PLoS One.* 2014 Apr 8;9(4):e94063. doi: 10.1371/journal.pone.0094063. PMID: 24714591.
131. Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretić L, Seidal D, Zander T, Leenders F, George J, Müller C, Dahmen I, Pinther B, Bosco G, Konrad K, Altmüller J, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soltermann A, Brustugun OT, Helland Å, Solberg S, Lund-Iversen M, Ansén S, Stoelben E, Wright GM, Russell P, Wainer Z, Solomon B, Field JK, Hyde R, Davies MP, Heukamp LC, Petersen I, Perner S, Lovly C, **Cappuzzo F**, Travis WD, Wolf J, Vingron M, Brambilla E, Haas SA, Buettner R, Thomas RK. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. *Nat Commun.* 2014 Mar

27;5:3518. doi:10.1038/ncomms4518. PMID: 24670920.

132. Proietti A, Alì G, Pelliccioni S, Lupi C, Sensi E, Boldrini L, Servadio A, Chella A, Ribechini A, **Cappuzzo F**, Miccoli M, Fontanini G. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment. *Cancer Cytopathol.* 2014 Jun;122(6):445-53. doi: 10.1002/cncy.21418. PMID: 24648382.
133. **Cappuzzo F**, Sacconi A, Landi L, Ludovini V, Biagioni F, D'Incecco A, Capodanno A, Salvini J, Corgna E, Cupini S, Barbara C, Fontanini G, Crinò L, Blandino G. MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies. *Clin Colorectal Cancer.* 2014 Mar;13(1):37-45.e4. doi: 10.1016/j.clcc.2013.11.006. PMID: 24503111.
134. Gridelli C, de Marinis F, **Cappuzzo F**, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. *Clin Lung Cancer.* 2014 May;15(3):173-81. doi: 10.1016/j.clc.2013.12.002. PMID: 24486058.
135. Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. *Sci Transl Med.* 2013 Oct 30;5(209):209ra153. doi: 10.1126/scitranslmed.3006802. PMID: 24174329.
136. Landi L, **Cappuzzo F**. HER2 and lung cancer. *Expert Rev Anticancer Ther.* 2013 Oct;13(10):1219-28. doi: 10.1586/14737140.2013.846830. PMID: 24134423.
137. Stahel R, Peters S, Baas P, Brambilla E, **Cappuzzo F**, De Ruyscher D, Eberhardt WE, Felip E, Fennell D, Marchetti A, Paz-Ares L, Adjei AA. Strategies for improving outcomes in NSCLC: a look to the future. *Lung Cancer.* 2013 Dec;82(3):375-82. doi: 10.1016/j.lungcan.2013.08.025. PMID: 24094287.
138. Mazières J, Brugger W, **Cappuzzo F**, Middel P, Frosch A, Bara I, Klingelschmitt G, Klughammer B. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study. *Lung Cancer.* 2013 Nov;82(2):231-7. doi: 10.1016/j.lungcan.2013.07.016. PMID: 23972450.
139. Minuti G, D'Incecco A, **Cappuzzo F**. Targeted therapy for NSCLC with driver mutations. *Expert Opin Biol Ther.* 2013 Oct;13(10):1401-12. doi: 10.1517/14712598.2013.827657. PMID: 23930754.
140. Capodanno A, Boldrini L, Proietti A, Alì G, Pelliccioni S, Niccoli C, D'Incecco A, **Cappuzzo F**, Chella A, Lucchi M, Mussi A, Fontanini G. Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features. *Int J Oncol.* 2013 Sep;43(3):765-74. doi: 10.3892/ijco.2013.2003. PMID: 23820752.
141. Landi L, Minuti G, D'Incecco A, Salvini J, **Cappuzzo F**. MET overexpression and gene amplification in NSCLC: a clinical perspective. *Lung Cancer (Auckl).* 2013 Jun 18;4:15-25. doi: 10.2147/LCTT.S35168. PMID: 28210131.
142. D'Arcangelo M, D'Incecco A, **Cappuzzo F**. Rare mutations in non-small-cell lung cancer. *Future Oncol.* 2013 May;9(5):699-711. doi: 10.2217/fon.13.16. PMID: 23647298.
143. D'Arcangelo M, **Cappuzzo F**. Erlotinib in the first-line treatment of non-small-cell lung cancer. *Expert Rev Anticancer Ther.* 2013 May;13(5):523-33. doi:10.1586/era.13.23. PMID: 23617344.
144. D'Arcangelo M, **Cappuzzo F**. Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer. *Biologics.* 2013;7:61-8.

doi:10.2147/BTT.S28908. PMID: 23493885.

145. Landi L, Minuti G, D'Incecco A, **Cappuzzo F**. Targeting c-MET in the battle against advanced nonsmall-cell lung cancer. *Curr Opin Oncol*. 2013 Mar;25(2):130-6. doi: 10.1097/CCO.0b013e32835daf37. PMID: 23385860.
146. Hirsch FR, Jänne PA, Eberhardt WE, **Cappuzzo F**, Thatcher N, Pirker R, Choy H, Kim ES, Paz-Ares L, Gandara DR, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA, Mok TS. Epidermal growth factor receptor inhibition in lung cancer: status 2012. *J Thorac Oncol*. 2013 Mar;8(3):373-84. doi: 10.1097/JTO.0b013e31827ed0ff. PMID:23370315.
147. Landi L, **Cappuzzo F**. Irreversible EGFR-TKIs: dreaming perfection. *Transl Lung Cancer Res*. 2013 Feb;2(1):40-9. doi: 10.3978/j.issn.2218-6751.2012.12.05. PMID: 25806203.
148. Martin V, Landi L, Molinari F, Fountzilias G, Geva R, Riva A, Saletti P, De Dosso S, Spitale A, Tejpar S, Kalogeras KT, Mazzucchelli L, Frattini M, **Cappuzzo F**. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. *Br J Cancer*. 2013 Feb 19;108(3):668-75. doi: 10.1038/bjc.2013.4. PMID: 23348520.
149. Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, Plenker D, Leenders F, Sun R, Zander T, Menon R, Koker M, Dahmen I, Müller C, Di Cerbo V, Schildhaus HU, Altmüller J, Baessmann I, Becker C, de Wilde B, Vandesompele J, Böhm D, Ansén S, Gabler F, Wilkening I, Heynck S, Heuckmann JM, Lu X, Carter SL, Cibulskis K, Banerji S, Getz G, Park KS, Rauh D, Grütter C, Fischer M, Pasqualucci L, Wright G, Wainer Z, Russell P, Petersen I, Chen Y, Stoelben E, Ludwig C, Schnabel P, Hoffmann H, Muley T, Brockmann M, Engel-Riedel W, Muscarella LA, Fazio VM, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman DA, Snijders PJ, **Cappuzzo F**, Ligorio C, Damiani S, Field J, Solberg S, Brustugun OT, Lund-Iversen M, Sängler J, Clement JH, Soltermann A, Moch H, Weder W, Solomon B, Soria JC, Validire P, Besse B, Brambilla E, Brambilla C, Lantuejoul S, Lorimier P, Schneider PM, Hallek M, Pao W, Meyerson M, Sage J, Shendure J, Schneider R, Büttner R, Wolf J, Nürnberg P, Perner S, Heukamp LC, Brindle PK, Haas S, Thomas RK. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. *Nat Genet*. 2012 Oct;44(10):1104-10. doi: 10.1038/ng.2396. PMID: 22941188.
150. Meulenbeld HJ, Bleuse JP, Vinci EM, Raymond E, Vitali G, Santoro A, Dogliotti L, Berardi R, **Cappuzzo F**, Tagawa ST, Sternberg CN, Jannuzzo MG, Mariani M, Petroccione A, de Wit R. Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. *BJU Int*. 2013 Jan;111(1):44-52. doi: 10.1111/j.1464-410X.2012.11404.x. PMID: 22928785.
151. Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, **Cappuzzo F**, Incarbone M, Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-Garcia M, Doebele RC. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. *Clin Cancer Res*. 2012 Sep 1;18(17):4570-9. doi: 10.1158/1078-0432.CCR-12-0550. PMID: 22919003.
152. Minuti G, **Cappuzzo F**, Duchnowska R, Jassem J, Fabi A, O'Brien T, Mendoza AD, Landi L, Biernat W, Czartoryska-Arlukowicz B, Jankowski T, Zuziak D, Zok J, Szostakiewicz B, Foszczyńska-Kłoda M, Tempnińska-Szałach A, Rossi E, Varella-Garcia M. Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. *Br J Cancer*. 2012 Aug 21;107(5):793-9. doi: 10.1038/bjc.2012.335. PMID:22850551.
153. Landi L, **Cappuzzo F**. Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference? *J Thorac Dis*. 2012 Apr 1;4(2):226-8. doi: 10.3978/j.issn.2072-1439.2012.03.14. PMID: 22833835.

154. Tibaldi C, Camerini A, D'Incecco A, Vasile E, Fabbri A, Amoroso D, **Cappuzzo F**. First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly 'unfrail' patients with advanced non-small-cell lung cancer: a multicenter phase II study. *J Cancer Res Clin Oncol*. 2012 Dec;138(12):2003-8. doi: 10.1007/s00432-012-1280-5. PMID: 22767317.
155. Califano R, Landi L, **Cappuzzo F**. Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. *Drugs*. 2012 Jun 19;72 Suppl 1:28-36. doi: 10.2165/1163012-S0-000000000-00000. PMID: 22712795.
156. **Cappuzzo F**. Management of non-small cell lung cancer: focus on erlotinib. Foreword. *Drugs*. 2012 Jun 19;72 Suppl 1:1-2. doi: 10.2165/1163029-S0-000000000-00000. PMID: 22712791.
157. Landi L, **Cappuzzo F**. EGFR TKIs as maintenance therapy in NSCLC: Finding the old in the new INFORMATION. *Transl Lung Cancer Res*. 2012 Jun;1(2):160-2. doi: 10.3978/j.issn.2218-6751.2012.06.05. PMID: 25806176.
158. **Cappuzzo F**, Cho YG, Sacconi A, Ali G, Siclari O, Incarbone M, Destro A, Terracciano L, Fontanini G, Marchetti A, Roncalli M, Varella-Garcia M. p95HER2 truncated form in resected non-small cell lung cancer. *J Thorac Oncol*. 2012 Mar;7(3):520-7. doi: 10.1097/JTO.0b013e318249e13f. Erratum in: *J Thorac Oncol*. 2012 Jun;7(6):1065. PMID: 22307009.
159. Metro G, Duranti S, Fischer MJ, **Cappuzzo F**, Crinò L. Emerging drugs for small cell lung cancer--an update. *Expert Opin Emerg Drugs*. 2012 Mar;17(1):31-6. doi: 10.1517/14728214.2012.656588. Epub 2012 Jan 31. PMID: 22288522.
160. Gridelli C, de Marinis F, Di Maio M, Ardizzoni A, Belani CP, **Cappuzzo F**, Ciardiello F, Fidias P, Paz-Ares L, Perrone F, Pirker R, De Petris L, Stahel R. Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. *Lung Cancer*. 2012 Jun;76(3):269-79. doi: 10.1016/j.lungcan.2011.12.011. PMID: 22266040.
161. D'Arcangelo M, **Cappuzzo F**. K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value. *ISRN Mol Biol*. 2012 May 14;2012:837306. doi: 10.5402/2012/837306. PMID: 27398239.
162. Sartore-Bianchi A, Fieuws S, Veronese S, Moroni M, Personeni N, Frattini M, Torri V, **Cappuzzo F**, Vander Borghet S, Martin V, Skokan M, Santoro A, Gambacorta M, Tejpar S, Varella-Garcia M, Siena S. Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. *J Clin Pathol*. 2012 Mar;65(3):218-23. doi: 10.1136/jclinpath-2011-200353. Epub 2011 Nov 30. Erratum in: *J Clin Pathol*. 2012 Jul;65(7):674.
163. Soria JC, Mok TS, **Cappuzzo F**, Jänne PA. EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. *Cancer Treat Rev*. 2012 Aug;38(5):416-30. doi: 10.1016/j.ctrv.2011.10.003. PMID: 22119437.
164. Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D'Emidio S, Catalano V, Sisti V, Ligorio C, Andreoni F, Rulli E, Di Oto E, Fiorentini G, Zingaretti C, De Nictolis M, **Cappuzzo F**, Magnani M. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. *J Clin Oncol*. 2011 Dec 20;29(36):4789-95. doi: 10.1200/JCO.2011.36.7706. PMID: 22042954.
165. Gately K, O'Flaherty J, **Cappuzzo F**, Pirker R, Kerr K, O'Byrne K. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC. *J Clin Pathol*. 2012 Jan;65(1):1-7. doi: 10.1136/jclinpath-2011-200275. PMID: 22039281.

166. Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whittom R, Ward C, Mayne K, Trunzer K, **Cappuzzo F**. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. *J Clin Oncol*. 2011 Nov 1;29(31):4113-20. doi:10.1200/JCO.2010.31.8162. Epub 2011 Oct 3. Erratum in: *J Clin Oncol*. 2011 Dec 10;29(35):4725. PMID: 21969500.
167. D'Incecco A, **Cappuzzo F**. Gefitinib for non-small-cell lung cancer treatment. *Expert Opin Drug Saf*. 2011 Nov;10(6):987-96. doi:10.1517/14740338.2011.617738. PMID: 21905963.
168. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, **Cappuzzo F**, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K, Jänne PA. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. *Sci Transl Med*. 2011 Sep 7;3(99):99ra86. doi: 10.1126/scitranslmed.3002442. PMID: 21900593.
169. Landi L, **Cappuzzo F**. Targeted therapies: Front-line therapy in lung cancer with mutations in EGFR. *Nat Rev Clin Oncol*. 2011 Aug 30;8(10):571-3. doi: 10.1038/nrclinonc.2011.135. PMID: 21878894.
170. Tibaldi C, Giovannetti E, Tiseo M, Leon LG, D'Incecco A, Loosekoot N, Bartolotti M, Honeywell R, **Cappuzzo F**, Ardizzoni A, Peters GJ. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. *Ann Oncol*. 2012 Mar;23(3):670-677. doi: 10.1093/annonc/mdr280. PMID: 21652582.
171. Coudert B, Ciuleanu T, Park K, Wu YL, Giaccone G, Brugger W, Gopalakrishna P, **Cappuzzo F**; SATURN Investigators. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. *Ann Oncol*. 2012 Feb;23(2):388-94. doi: 10.1093/annonc/mdr125. PMID: 21610154.
172. **Cappuzzo F**, Camidge DR, Varella-Garcia M. Is FISH floating or still swimming in the lung cancer ocean? *Ann Oncol*. 2011 Mar;22(3):493-499. doi: 10.1093/annonc/mdq752. Erratum in: *Ann Oncol*. 2011 Jun;22(6):1467. PMID: 21292645.
173. Tibaldi C, Giovannetti E, Vasile E, Boldrini L, Gallegos-Ruiz MI, Bernardini I, Incensati R, Danesi R, **Cappuzzo F**, Peters GJ, Fontanini G. Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients. *J Thorac Oncol*. 2011 Feb;6(2):395-6. doi: 10.1097/JTO.0b013e3182059a6f. PMID: 21252721.
174. Gridelli C, De Marinis F, Di Maio M, Cortinovis D, **Cappuzzo F**, Mok T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. *Lung Cancer*. 2011 Apr;72(1):3-8. doi: 10.1016/j.lungcan.2010.12.009. PMID: 21216488.
175. Gridelli C, De Marinis F, Di Maio M, Cortinovis D, **Cappuzzo F**, Mok T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. *Lung Cancer*. 2011 Mar;71(3):249-57. doi: 10.1016/j.lungcan.2010.12.008. PMID: 21216486.
176. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schöttle J, Leenders F, Gabler F, Dabow I, Querings S, Heukamp LC, Balke-Want H, Ansén S, Rauh D, Baessmann I, Altmüller J, Wainer Z, Conron M,

- Wright G, Russell P, Solomon B, Brambilla E, Brambilla C, Lorimier P, Sollberg S, Brustugun OT, Engel-Riedel W, Ludwig C, Petersen I, Sanger J, Clement J, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman D, **Cappuzzo F**, Ligorio C, Damiani S, Hallek M, Beroukhim R, Pao W, Klebl B, Baumann M, Buettner R, Ernestus K, Stoelben E, Wolf J, Nurnberg P, Perner S, Thomas RK. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. *Sci Transl Med*. 2010 Dec 15;2(62):62ra93. doi: 10.1126/scitranslmed.3001451. Erratum in: *Sci Transl Med*. 2011 Jan 19;3(66):66er2. Erratum in: *Sci Transl Med*. 2012 Apr 18;4(130):130er2. PMID: 21160078.
177. De Maio E, Tibaldi C, D'Incecco A, Bursi S, Barbara C, Cupini S, Di Marsico R, D'Arcangelo M, Landi L, Minuti G, **Cappuzzo F**. Consequences of targeted treatments for second-line therapy. *Ann Oncol*. 2010 Oct;21 Suppl 7:vii234-40. doi: 10.1093/annonc/mdq280. PMID: 20943621.
178. Grossi F, Kubota K, **Cappuzzo F**, de Marinis F, Gridelli C, Aita M, Douillard JY. Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. *Oncologist*. 2010;15(10):1102-12. doi: 10.1634/theoncologist.2010-0322. Epub 2010 Oct 7. PMID: 20930102; PMCID: PMC3227896.
179. Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E, Dietel M, Marchetti A, Manegold C, Schirmacher P, Thomas M, Rosell R, **Cappuzzo F**, Stahel R; European EGFR Workshop Group. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. *J Thorac Oncol*. 2010 Oct;5(10):1706-13. doi: 10.1097/JTO.0b013e3181f1c8de. PMID: 20871269.
180. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogerias KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, **Cappuzzo F**, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol*. 2010 Aug;11(8):753-62. doi: 10.1016/S1470-2045(10)70130-3. PMID: 20619739.
181. **Cappuzzo F**, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, Esteban E, Molinier O, Brugger W, Melezınek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. *Lancet Oncol*. 2010 Jun;11(6):521-9. doi: 10.1016/S1470-2045(10)70112-1. PMID: 20493771.
182. Toschi L, **Cappuzzo F**. Impact of biomarkers on non-small cell lung cancer treatment. *Target Oncol*. 2010 Mar;5(1):5-17. doi: 10.1007/s11523-010-0132-y. PMID: 20443070.
183. Sterlacci W, **Cappuzzo F**, Savic S, Bubendorf L, Tzankov A. Anaplastic lymphoma kinase 1 detected by immunohistochemistry in non-small cell lungcancer: a promising feature? *Hum Pathol*. 2010 Apr;41(4):614-5; author reply 615-616. doi: 10.1016/j.humpath.2009.11.009. PMID: 20163822.
184. Toschi L, **Cappuzzo F**. Clinical implications of MET gene copy number in lung cancer. *Future Oncol*. 2010 Feb;6(2):239-47. doi: 10.2217/fon.09.164. PMID: 20146583.
185. Stahel R, Baas P, Faivre-Finn C, Dooms C, Passlick B, Mazieres J, **Cappuzzo F**, Fruh M, Sorensen JB, Blackhall F, Taron M, Gridelli C, O'Byrne K, Rosell R. Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP). *Lung Cancer*. 2010 Apr;68(1):121-4. doi:

10.1016/j.lungcan.2010.01.010. PMID: 20138388.

186. Varella-Garcia M, Diebold J, Eberhard DA, Geenen K, Hirschmann A, Kockx M, Nagelmeier I, Rüschoff J, Schmitt M, Arbogast S, **Cappuzzo F**. EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. *J Clin Pathol*. 2009 Nov;62(11):970-7. doi: 10.1136/jcp.2009.066548. PMID: 19861557.
187. Marchetti A, Milella M, Felicioni L, **Cappuzzo F**, Irtelli L, Del Grammastro M, Sciarrotta M, Malatesta S, Nuzzo C, Finocchiaro G, Perrucci B, Carlone D, Gelibter AJ, Ceribelli A, Mezzetti A, Iacobelli S, Cognetti F, Buttitta F. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. *Neoplasia*. 2009 Oct;11(10):1084-92. doi: 10.1593/neo.09814. PMID: 19794967.
188. Leidner RS, Fu P, Clifford B, Hamdan A, Jin C, Eisenberg R, Boggon TJ, Skokan M, Franklin WA, **Cappuzzo F**, Hirsch FR, Varella-Garcia M, Halms B. Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. *J Clin Oncol*. 2009 Nov 20;27(33):5620-6. doi:10.1200/JCO.2009.23.1431. Epub 2009 Sep 28. PMID: 19786660; PMCID: PMC3329938.
189. **Cappuzzo F**, Tallini G, Finocchiaro G, Wilson RS, Ligorio C, Giordano L, Toschi L, Incarbone M, Cavina R, Terracciano L, Roncalli M, Alloisio M, Varella-Garcia M, Franklin WA, Santoro A. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. *Ann Oncol*. 2010 Mar;21(3):562-567. doi: 10.1093/annonc/mdp357. PMID: 19767315.
190. Metro G, **Cappuzzo F**. Emerging drugs for small-cell lung cancer. *Expert Opin Emerg Drugs*. 2009 Dec;14(4):591-606. doi: 10.1517/14728210903206983. PMID: 19694501.
191. Hirsch FR, Varella-Garcia M, **Cappuzzo F**. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. *Oncogene*. 2009 Aug;28 Suppl 1:S32-7. doi: 10.1038/onc.2009.199. PMID: 19680294.
192. Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L, **Cappuzzo F**, Sharma S, Gross SH, Dimitrijevic S, Di Scala L, Gardner H, Nogova L, Papadimitrakopoulou V. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. *Ann Oncol*. 2009 Oct;20(10):1674-81. doi: 10.1093/annonc/mdp060. PMID: 19549709.
193. Infante M, Cavuto S, Lutman FR, Brambilla G, Chiesa G, Ceresoli G, Passera E, Angeli E, Chiarenza M, Aranzulla G, Cariboni U, Errico V, Inzirillo F, Bottoni E, Voulaz E, Alloisio M, Destro A, Roncalli M, Santoro A, Ravasi G; DANTE Study Group. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. *Am J Respir Crit Care Med*. 2009 Sep 1;180(5):445-53. doi: 10.1164/rccm.200901-0076OC. Epub 2009 Jun 11. PMID: 19520905.
194. **Cappuzzo F**, Marchetti A, Skokan M, Rossi E, Gajopathy S, Felicioni L, Del Grammastro M, Sciarrotta MG, Buttitta F, Incarbone M, Toschi L, Finocchiaro G, Destro A, Terracciano L, Roncalli M, Alloisio M, Santoro A, Varella-Garcia M. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. *J Clin Oncol*. 2009 Apr 1;27(10):1667-74. doi: 10.1200/JCO.2008.19.1635. PMID: 19255323.
195. **Cappuzzo F**, Varella-Garcia M, Rossi E, Gajopathy S, Valente M, Drabkin H, Gemmill R. MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib. *J Thorac Oncol*. 2009 Apr;4(4):472-8. doi: 10.1097/JTO.0b013e31819a5767. PMID: 19204574.

196. Toschi L, **Cappuzzo F**. Gemcitabine for the treatment of advanced nonsmall cell lung cancer. *Onco Targets Ther.* 2009 Feb 18;2:209-17. doi: 10.2147/ott.s4645. PMID: 20616908.
197. **Cappuzzo F**, Jänne PA, Skokan M, Finocchiaro G, Rossi E, Ligorio C, Zucali PA, Terracciano L, Toschi L, Roncalli M, Destro A, Incarbone M, Alloisio M, Santoro A, Varella-Garcia M. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. *Ann Oncol.* 2009 Feb;20(2):298-304. doi: 10.1093/annonc/mdn635. PMID: 18836087.
198. Crinò L, **Cappuzzo F**, Zatloukal P, Reck M, Pesek M, Thompson JC, Ford HE, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Duffield EL, Armour AA, Speake G, Cullen M. Gefitinib versus vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. *J Clin Oncol.* 2008 Sep 10;26(26):4253-60. doi: 10.1200/JCO.2007.15.0672. PMID: 18779612.
199. **Cappuzzo F**, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, Rimassa L, Rossi E, Ligorio C, Di Tommaso L, Holmes AJ, Toschi L, Tallini G, Destro A, Roncalli M, Santoro A, Jänne PA. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. *Br J Cancer.* 2008 Jul 8;99(1):83-9. doi: 10.1038/sj.bjc.6604439. Epub 2008 Jun 24. PMID: 18577988; PMCID: PMC2453041.
200. Ceresoli GL, Castagneto B, Zucali PA, Favaretto A, Mencoboni M, Grossi F, Cortinovis D, Del Conte G, Ceribelli A, Bearz A, Salamina S, De Vincenzo F, **Cappuzzo F**, Marangolo M, Torri V, Santoro A. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. *Br J Cancer.* 2008 Jul 8;99(1):51-6. doi: 10.1038/sj.bjc.6604442. PMID: 18542071.
201. Incarbone M, Ceresoli GL, Di Tommaso L, **Cappuzzo F**, Inzirillo F, Infante M, Alloisio M. Primary pulmonary meningioma: report of a case and review of the literature. *Lung Cancer.* 2008 Dec;62(3):401-7. doi: 10.1016/j.lungcan.2008.03.031. PMID: 18486986.
202. Metro G, Finocchiaro G, Toschi L, Bartolini S, Magrini E, Cancellieri A, Trisolini R, Castaldini L, Tallini G, Crino L, **Cappuzzo F**. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). *Rev Recent Clin Trials.* 2006 Jan;1(1):1-13. doi: 10.2174/157488706775246157. PMID: 18393776.
203. **Cappuzzo F**. EGFR FISH versus mutation: different tests, different end-points. *Lung Cancer.* 2008 May;60(2):160-5. doi: 10.1016/j.lungcan.2008.02.008. PMID: 18367287.
204. Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, **Cappuzzo F**, Salamina S, Soto Parra HJ, Santoro A. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. *Cancer.* 2008 Apr 1;112(7):1555-61. doi: 10.1002/cncr.23337. PMID: 18286536.
205. **Cappuzzo F**, Finocchiaro G, Rossi E, Jänne PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello F, Pressiani T, Destro A, Roncalli M, Crino L, Franklin WA, Santoro A, Varella-Garcia M. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. *Ann Oncol.* 2008 Apr;19(4):717-23. doi: 10.1093/annonc/mdm492. PMID: 17974556.
206. Infante M, Lutman FR, Cavuto S, Brambilla G, Chiesa G, Passera E, Angeli E, Chiarenza M, Aranzulla G, Cariboni U, Alloisio M, Incarbone M, Testori A, Destro A, **Cappuzzo F**, Roncalli M, Santoro A, Ravasi G; DANTE Study Group. Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial. *Lung Cancer.* 2008 Mar;59(3):355-63. doi: 10.1016/j.lungcan.2007.08.040. PMID: 17936405.

207. Finocchiaro G, Toschi L, Garassino I, De Vincenzo F, Campagnoli E, Zucali P, Cavina R, Ceresoli GL, Santoro A, **Cappuzzo F**. EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients? *Expert Opin Med Diagn*. 2007 Oct;1(2):183-91. doi: 10.1517/17530059.1.2.183. PMID: 23489305.
208. Toschi L, **Cappuzzo F**, Jänne PA. Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer. *Ann Oncol*. 2007 Jul;18 Suppl 9:ix150-5. doi: 10.1093/annonc/mdm311. PMID: 17631569.
209. Ceresoli GL, Chiti A, Zucali PA, **Cappuzzo F**, De Vincenzo F, Cavina R, Rodari M, Poretti D, Lutman FR, Santoro A. Assessment of tumor response in malignant pleural mesothelioma. *Cancer Treat Rev*. 2007 Oct;33(6):533-41. doi: 10.1016/j.ctrv.2007.07.012. PMID: 17764849.
210. Toschi L, Finocchiaro G, Ceresoli GL, Zucali PA, Cavina R, Garassino I, De Vincenzo F, Santoro A, **Cappuzzo F**. Is gemcitabine cost effective in cancer treatment? *Expert Rev Pharmacoecon Outcomes Res*. 2007 Jun;7(3):239-49. doi: 10.1586/14737167.7.3.239. PMID: 20528311.
211. **Cappuzzo F**, Ligorio C, Jänne PA, Toschi L, Rossi E, Trisolini R, Paioli D, Holmes AJ, Magrini E, Finocchiaro G, Bartolini S, Cancellieri A, Ciardiello F, Patelli M, Crino L, Varella-Garcia M. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization- positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. *J Clin Oncol*. 2007 Jun 1;25(16):2248-55. doi: 10.1200/JCO.2006.09.4300. PMID: 17538169.
212. **Cappuzzo F**, Toschi L, Finocchiaro G, Ligorio C, Santoro A. Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges. *Int J Biol Markers*. 2007 Jan-Mar;22(1 Suppl 4):S10-23. PMID:17520577.
213. **Cappuzzo F**, Ligorio C, Toschi L, Rossi E, Trisolini R, Paioli D, Magrini E, Finocchiaro G, Bartolini S, Cancellieri A, Hirsch FR, Crino L, Varella-Garcia M. EGFR and HER2 gene copy number and response to first-line chemotherapy inpatients with advanced non-small cell lung cancer (NSCLC). *J Thorac Oncol*. 2007 May;2(5):423-9. doi: 10.1097/01.JTO.0000268676.79872.9b. Erratum in: *J Thorac Oncol*. 2007 Jul;2(7):676. Ligorio, Claudio [corrected to Ligorio, Claudia]. PMID: 17473658.
214. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, **Cappuzzo F**, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science*. 2007 May 18;316(5827):1039-43. doi: 10.1126/science.1141478. PMID: 17463250.
215. **Cappuzzo F**. Predictive factors for response and for resistance to tyrosine kinase inhibitor therapy in lung cancer. *J Thorac Oncol*. 2007 May;2(5 Suppl):S12-4. doi: 10.1097/01.JTO.0000268634.17956.5e. PMID: 17457222.
216. Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, Jacobson F, Johnson BE, Hirsch F, Brambilla E, Flieder DB, Geisinger KR, Thunnissen F, Kerr K, Yankelevitz D, Franks TJ, Galvin JR, Henderson DW, Nicholson AG, Hasleton PS, Roggli V, Tsao MS, **Cappuzzo F**, Vazquez M. Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. *J Thorac Oncol*. 2006 Nov;1(9 Suppl):S13-9. PMID: 17409995.
217. Hirsch FR, Varella-Garcia M, **Cappuzzo F**, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, Franklin WA, Bunn PA Jr. Combination of EGFR gene copy number and

- protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. *Ann Oncol.* 2007 Apr;18(4):752-60. doi: 10.1093/annonc/mdm003. PMID: 17317677.
218. Toschi L, **Cappuzzo F**. Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. *Oncologist.* 2007 Feb;12(2):211-20. doi: 10.1634/theoncologist.12-2-211. PMID: 17296817.
 219. **Cappuzzo F**, Toschi L, Finocchiaro G, Ligorio C, Santoro A. Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges. *Int J Biol Markers.* 2007 S4 - Jan-Mar;22(4):10-23. doi: 10.5301/JBM.2008.5699. PMID: 28207110.
 220. **Cappuzzo F**. Should every lung cancer patient be tested for EGFR mutation? *Expert Opin Ther Targets.* 2006 Dec;10(6):789-91. doi: 10.1517/14728222.10.6.789. PMID: 17105366.
 221. Metro G, **Cappuzzo F**, Finocchiaro G, Toschi L, Crinò L. Development of gemcitabine in non-small cell lung cancer: the Italian contribution. *Ann Oncol.* 2006 May;17 Suppl 5:v37-46. doi: 10.1093/annonc/mdj948. PMID: 16807461.
 222. **Cappuzzo F**, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. *N Engl J Med.* 2006 Jun 15;354(24):2619-21. doi: 10.1056/NEJMc060020. PMID: 16775247.
 223. Dziadziuszko R, Witta SE, **Cappuzzo F**, Park S, Tanaka K, Danenberg PV, Barón AE, Crino L, Franklin WA, Bunn PA Jr, Varella-Garcia M, Danenberg KD, Hirsch FR. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. *Clin Cancer Res.* 2006 May 15;12(10):3078-84. doi: 10.1158/1078-0432.CCR-06-0106. PMID: 16707605.
 224. **Cappuzzo F**, Novello S, De Marinis F, Selvaggi G, Scagliotti GV, Barbieri F, Maur M, Papi M, Pasquini E, Bartolini S, Marini L, Crinò L. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. *Lung Cancer.* 2006 Jun;52(3):319-25. doi: 10.1016/j.lungcan.2006.03.004. PMID: 16630670.
 225. Metro G, Finocchiaro G, **Cappuzzo F**. Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. *Ann Oncol.* 2006 Mar;17 Suppl 2:ii42-45. doi: 10.1093/annonc/mdj920. PMID: 16608980.
 226. **Cappuzzo F**, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S, Finocchiaro G, Magrini E, Metro G, Cancellieri A, Trisolini R, Crino L, Bunn PA Jr, Santoro A, Franklin WA, Varella-Garcia M, Hirsch FR. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. *Ann Oncol.* 2006 Jul;17(7):1120-7. doi: 10.1093/annonc/mdl077. PMID: 16600976.
 227. Toschi L, Finocchiaro G, Bartolini S, Gioia V, **Cappuzzo F**. Role of gemcitabine in cancer therapy. *Future Oncol.* 2005 Feb;1(1):7-17. doi: 10.1517/14796694.1.1.7. PMID: 16555971.
 228. **Cappuzzo F**, Finocchiaro G, Metro G, Bartolini S, Magrini E, Cancellieri A, Trisolini R, Castaldini L, Tallini G, Crino L. Clinical experience with gefitinib: an update. *Crit Rev Oncol Hematol.* 2006 Apr;58(1):31-45. doi: 10.1016/j.critrevonc.2005.08.008. PMID: 16531062.
 229. **Cappuzzo F**, Toschi L, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Cancellieri A, Magrini E, Bemis L, Franklin WA, Crino L, Bunn PA Jr, Hirsch FR, Varella-Garcia M. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. *Br J Cancer.* 2005 Dec 12;93(12):1334-40. doi: 10.1038/sj.bjc.6602865. PMID: 16288303.

230. Venturini M, Bighin C, Monfardini S, **Cappuzzo F**, Olmeo N, Durando A, Puglisi F, Nicoletto O, Lambiase A, Del Mastro L. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. *Breast Cancer Res Treat.* 2006 Jan;95(1):45-53. doi: 10.1007/s10549-005-9030-x. PMID: 16267615.
231. **Cappuzzo F**, Finocchiaro G, Trisolini R, Toschi L, Bartolini S, Metro G, Crinò L. Perspectives on salvage therapy for non-small-cell lung cancer. *Oncology (Williston Park).* 2005 Jul;19(8):989-95; discussion 995-6, 999, 1003-4, passim. PMID: 16131043.
232. **Cappuzzo F**, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn PA Jr, Hirsch FR. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. *J Clin Oncol.* 2005 Aug 1;23(22):5007-18. doi: 10.1200/JCO.2005.09.111. PMID: 16051952.
233. **Cappuzzo F**, Novello S, De Marinis F, Franciosi V, Maur M, Ceribelli A, Lorusso V, Barbieri F, Castaldini L, Crucitta E, Marini L, Bartolini S, Scagliotti GV, Crinò L. Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer. *Br J Cancer.* 2005 Jul 11;93(1):29-34. doi: 10.1038/sj.bjc.6602667. PMID: 15956971.
234. **Cappuzzo F**. Erlotinib in gliomas: should selection be based on EGFR and Akt analyses? *J Natl Cancer Inst.* 2005 Jun 15;97(12):868-9. doi: 10.1093/jnci/dji169. PMID: 15956643.
235. Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, Jacobson F, Johnson BE, Hirsch F, Brambilla E, Flieder DB, Geisinger KR, Thunnissen F, Kerr K, Yankelevitz D, Franks TJ, Galvin JR, Henderson DW, Nicholson AG, Hasleton PS, Roggli V, Tsao MS, **Cappuzzo F**, Vazquez M. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. *J Clin Oncol.* 2005 May 10;23(14):3279-87. doi: 10.1200/JCO.2005.15.776. PMID: 15886315.
236. **Cappuzzo F**, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. *J Natl Cancer Inst.* 2005 May 4;97(9):643-55. doi: 10.1093/jnci/dji112. PMID: 15870435.
237. Gregorc V, Ceresoli GL, Floriani I, Spreafico A, Bencardino KB, Ludovini V, Pistola L, Mihaylova Z, Tofanetti FR, Ferraldeschi M, Torri V, **Cappuzzo F**, Crinò L, Tonato M, Villa E. Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. *Clin Cancer Res.* 2004 Sep 15;10(18 Pt 1):6006-12. doi: 10.1158/1078-0432.CCR-03-0770. PMID: 15447984.
238. **Cappuzzo F**, Bartolini S, Calandri C, Crinò L. Induction therapy for early-stage non-small-cell lung cancer. *Oncology (Williston Park).* 2004 Jul;18(8 Suppl 5):32-7. PMID: 15339057.
239. **Cappuzzo F**, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crinò L. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. *J Natl Cancer Inst.* 2004 Aug 4;96(15):1133-41. doi: 10.1093/jnci/djh217. PMID: 15292385.
240. Ceresoli GL, **Cappuzzo F**, Gregorc V, Bartolini S, Crinò L, Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. *Ann Oncol.* 2004 Jul;15(7):1042-7. doi: 10.1093/annonc/mdh276. PMID:

15205197.

241. **Cappuzzo F**, Bartolini S, Ceresoli GL, Tamberi S, Spreafico A, Lombardo L, Gregorc V, Toschi L, Calandri C, Villa E, Crinò L. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). *Br J Cancer*. 2004 Jan 12;90(1):82-6. doi: 10.1038/sj.bjc.6601470. PMID: 14710211; PMCID: PMC2395316.
242. **Cappuzzo F**, Mazzoni F, Gennari A, Donati S, Salvadori B, Orlandini C, Cetto GL, Molino A, Galligioni E, Mansutti M, Tumolo S, Lucentini A, Valduga F, Bartolini S, Crinò L, Conte PF. Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. *Br J Cancer*. 2004 Jan 12;90(1):31-5. doi: 10.1038/sj.bjc.6601518. PMID: 14710202.
243. **Cappuzzo F**, De Marinis F, Nelli F, Calandri C, Maestri A, Benedetti G, Migliorino MR, Cortesi E, Rastelli F, Martelli O, Andrucci M, Bartolini S, Crinò L. Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer. *Lung Cancer*. 2003 Dec;42(3):355-61. doi: 10.1016/s0169-5002(03)00365-9. PMID: 14644524.
244. **Cappuzzo F**, Bartolini S, Crinò L. Emerging drugs for non-small cell lung cancer. *Expert Opin Emerg Drugs*. 2003 May;8(1):179-92. doi: 10.1517/14728214.8.1.179. PMID: 14610920.
245. **Cappuzzo F**, Ardizzoni A, Soto-Parra H, Gridelli C, Maione P, Tiseo M, Calandri C, Bartolini S, Santoro A, Crinò L. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). *Lung Cancer*. 2003 Aug;41(2):227-31. doi:10.1016/s0169-5002(03)00189-2. PMID: 12871787.
246. **Cappuzzo F**, Calandri C, Bartolini S, Crinò L. ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases. *Br J Cancer*. 2003 Jul 21;89(2):246-7. doi: 10.1038/sj.bjc.6601116. PMID: 12865910.
247. **Cappuzzo F**, Gregorc V, Rossi E, Cancellieri A, Magrini E, Paties CT, Ceresoli G, Lombardo L, Bartolini S, Calandri C, de Rosa M, Villa E, Crino L. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. *J Clin Oncol*. 2003 Jul 15;21(14):2658-63. doi: 10.1200/JCO.2003.01.039. PMID: 12860941.
248. **Cappuzzo F**, Selvaggi G, Gregorc V, Mazzoni F, Betti M, Rita Migliorino M, Novello S, Maestri A, De Marinis F, Darwish S, De Angelis V, Nelli F, Bartolini S, Scagliotti GV, Tonato M, Crinò L. Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study. *Cancer*. 2003 Jul 1;98(1):128-34. doi: 10.1002/cncr.11460. PMID: 12833465.
249. **Cappuzzo F**. Medical treatment of brain metastases from lung cancer. *Suppl Tumori*. 2002 Jul-Aug;1(4):S58-9. PMID: 12415823.
250. Crinò L, **Cappuzzo F**. New platinum derivatives in advanced non-small cell lung cancer. *Suppl Tumori*. 2002 Jul-Aug;1(4):S24-5. PMID: 12415810.
251. Crinò L, **Cappuzzo F**. Present and future treatment of advanced non-small cell lung cancer. *Semin Oncol*. 2002 Jun;29(3 Suppl 9):9-16. doi: 10.1053/sonc.2002.34266. PMID: 12094333.
252. Crinò L, **Cappuzzo F**. Gemcitabine in non-small cell lung cancer. *Expert Opin Pharmacother*. 2002 Jun;3(6):745-53. doi: 10.1517/14656566.3.6.745. PMID: 12036414.

253. Crinò L, **Cappuzzo F**. Multimodality therapy for non-small cell lung cancer (NSCLC): ongoing Italian experiences in the adjuvant and neoadjuvant settings. *Lung Cancer*. 2001 Dec;34 Suppl 3:S45-7. doi: 10.1016/s0169-5002(01)00367-1. PMID: 11740993.
254. Crino L, **Cappuzzo F**. Rôle de la gemcitabine dans la chimiothérapie des stades avancés du cancer bronchique non à petites cellules: revue des principales études de phase II et III [Role of gemcitabine in the treatment of advanced non-small cell lung cancer: review of the main phase II and phase III trials]. *Anticancer Drugs*. 2001 Jul;12 Suppl 3:S9-13. French. PMID: 11556252.
255. **Cappuzzo F**, Rocha Lima CM, Sherman CA, Green MR. Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative. *Oncology (Williston Park)*. 2000 Jul;14(7 Suppl 4):7-14. PMID: 10960939.
256. **Cappuzzo F**, Mazzoni F, Maestri A, Di Stefano A, Calandri C, Crino L. Medical treatment of brain metastases from solid tumours. *Forum (Genova)*. 2000 Apr-Jun;10(2):137-48. PMID: 10875975.
257. Bozzetti F, Biganzoli L, Gavazzi C, **Cappuzzo F**, Carnaghi C, Buzzoni R, Dibartolomeo M, Baietta E. Glutamine supplementation in cancer patients receiving chemotherapy: a double-blind randomized study. *Nutrition*. 1997 Jul-Aug;13(7-8):748-51. doi: 10.1016/s0899-9007(97)83038-9. PMID: 9263281.
258. Bajetta E, **Cappuzzo F**. Carcinoma del colon-retto: strategia terapeutica in pazienti già sottoposti a metastasectomia [Colorectal carcinoma: therapeutic approach in patients already treated with metastasis resection]. *Ann Ital Chir*. 1996 Nov-Dec;67(6):827-30. Italian. PMID: 9214274.
259. Bajetta E, Di Leo A, Biganzoli L, Mariani L, **Cappuzzo F**, Di Bartolomeo M, Zilembo N, Artale S, Magnani E, Celio L, Buzzoni R, Carnaghi C. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. *J Clin Oncol*. 1996 Sep;14(9):2546-51. doi: 10.1200/JCO.1996.14.9.2546. PMID: 8823334.
260. Noberasco C, Bajetta E, Zilembo N, Di Leo A, **Cappuzzo F**, Bartoli C, Bono A, Bichisao E. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer. *Oncology*. 1995 Nov-Dec;52(6):454-7. doi: 10.1159/000227510. PMID: 7478430.
261. Bajetta E, Colleoni M, Di Bartolomeo M, Buzzoni R, Bozzetti F, Doci R, Somma L, **Cappuzzo F**, Stampino CG, Guenzi A, et al. Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. *J Clin Oncol*. 1995 Oct;13(10):2613-9. doi: 10.1200/JCO.1995.13.10.2613. PMID: 7595715.

CAPITOLI DI LIBRI

1. **Cappuzzo F**, Le Pechoux C, and Le Chevalier T. Small cell lung cancer. In: *Oncologic Therapies*, Editors Vokes/Golomb, Springer-Verlag, 620-631, 1998
2. **Cappuzzo F**, Zappalà A, and Le Chevalier T. Should all stage IV Non-Small Cell Lung Cancer be treated palliatively? In: *Medical Radiology. Diagnostic Imaging and Radiation Oncology*. Editors P. Van Houtte, J. Klastersky, P. Rocmans. *Progress and Perspectives in The Treatment of Lung Cancer*. Springer-Verlag, 183-189, 1999
3. **Cappuzzo F**, Le Pechoux C, and Le Chevalier T. Small cell lung cancer. In: *Oncologic Therapies*, Editors Vokes/Golomb, Springer-Verlag, 407-414, 2002
4. **Cappuzzo F**, Bartolini S, Crino L. Targeted therapies for Non-Small Cell Lung Cancer (NSCLC). In: *Focus on lung cancer*, Nova publisher, 305-329, 2004
5. Finocchiaro G, Bartolini S, **Cappuzzo F**, Crino L. Tumori del polmone. In: *Terapia molecolare in oncologia*. Poletto Editore, 2005:182-200.
6. Bidoli P, Cortinovis D, **Cappuzzo F**, Pastorino U. Neoplasie del polmone. In: *Medicina Oncologica* by G. Bonadonna, G. Robustelli Della Cuna, P. Valagussa, Masson Editore, 2006
7. **Cappuzzo F**. *Guide to Targeted Therapies: EGFR mutations in NSCLC*. Springer 2014
8. **Cappuzzo F**. *Guide to targeted therapies: treatment resistance in lung cancer*. Springer 2015

ALTRE PUBBLICAZIONI

1. Bajetta E, Rimassa L, Di Bartolomeo M, Carnaghi C, Somma L, Del Vecchio M, Artale S, **Cappuzzo F**, Magnani E, Gallo Stampino C. Le fluoropirimidine: Dal fluorouracile alle nuove molecole. *Argomenti di Oncologia* 17: 1-17, 1996
2. Bajetta E, **Cappuzzo F**, Rimassa L, Giannetta L, Buzzoni R, Noberasco C, Del Vecchio M, Cassata A, Procopio G, Bedini VA, Ravasi G. Terapia medica del carcinoma polmonare non a piccole cellule: Stato dell'arte e prospettive future. *Argomenti di Oncologia* 18: 7-24, 1997
3. **Cappuzzo F** and Le Chevalier T. Non-Small Cell Lung Cancer: First line chemotherapy for advanced disease. *Perspective in lung cancer*, 1997
4. Crinò L, **Cappuzzo F**. Tumori polmonari e del mediastino. *Tecne*, November 1999
5. Crinò L, **Cappuzzo F**. Tumori polmonari e del mediastino. *Tecne*, November 2000
6. Crinò L, **Cappuzzo F**. Tumori polmonari e del mediastino. *Tecne*, May 2001
7. Crinò L, **Cappuzzo F**. Tumori polmonari e del mediastino. *Tecne*, November 2001
8. Crinò L, **Cappuzzo F**. Tumori polmonari e del mediastino. *Tecne*, May 2002
9. Crinò L, **Cappuzzo F**. Tumori polmonari e del mediastino. *Tecne*, May 2003
10. **Cappuzzo F**. Molecular markers to predict response to gefitinib: EGFR, ERBB-2 or more? *J Clin Oncol* 22:2036-2037, 2004
11. Cappuzzo F. Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. *J Natl Cancer Inst* 96: 1795-1796, 2004
12. Cappuzzo F. Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. *J Natl Cancer Inst* 97: 461-462, 2005
13. Hirsch FR, and **Cappuzzo F**. EGFR-targeted therapies in NSCLC: meeting patients needs. *Signal*, 2004
14. Bartolini S, Toschi L, Finocchiaro G, Metro G, and **Cappuzzo F**. Use of molecular screening for clinical trials with Epidermal Growth Factor Receptor (EGFR) inhibitors. *Signal*, 2006
15. Toschi L, **Cappuzzo F**. EGFR inhibition in cancer therapy. *Supportive and Palliative Cancer Care* 2006;37-42
16. **Cappuzzo F**. Should every lung cancer patient be tested for EGFR mutation? *Expert opinion on therapeutic targets* 2007; 10(6):789-91.
17. Finocchiaro G, Toschi L, Garassino I, De Vincenzo F, Campagnoli E, Zucali P, Cavina R, Ceresoli GL, Santoro A, **Cappuzzo F**. EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small-cell lung cancer patients? *Expert Opin Med Diagn* 2007;1:1-9
18. Toschi L, Finocchiaro G, Garassino I, De Vincenzo F, Campagnoli E, Ceresoli GL, Cavina R, Zucali PA, Santoro A, **Cappuzzo F**. Optimizing anti-EGFR strategies in cancer treatment. *Current Cancer Therapy Reviews* 2007.
19. Toschi L, Finocchiaro G, Garassino I, De Vincenzo F, Campagnoli E, Ceresoli GL, Cavina R, Zucali PA, Santoro A, **Cappuzzo F**. Optimizing anti-EGFR strategies in cancer treatment. *Current Cancer Therapy Review* 2007;3:267-275
20. Califano R, Blackhall FH, Finocchiaro G, Toschi L, Thatcher N, **Cappuzzo F**, Crinò L. EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data? *Targ Oncol* 2008
21. Toschi L, **Cappuzzo F**. Gefitinib in patients of Asiatic ethnicity or never smokers. *Asia-Pacific Journal of Oncology/Hematology* 2009; 1:1-9.

Il sottoscritto, consapevole delle sanzioni previste dal codice penale, e dalle leggi speciali nei confronti di chiunque rilasci dichiarazioni mendaci, consapevole altresì della possibilità di decadere dai benefici conseguenti a eventuali provvedimenti emanati sulla base di dichiarazione non veritiera dichiara:

- *che quanto dichiarato nella domanda e nel curriculum vitae corrisponde a verità – art. 46, D.P.R. 445/2000;*
- *che le copie di documenti, titoli e pubblicazioni allegati alla presente domanda sono conformi agli originali – art.47, D.P.R. 445/2000.*

Roma, 25.01.2022